基于TGF-β/Smad/ERK信号转导通路的补阳还五汤拮抗肺纤维化机制研究
|
摘要
肺纤维化(pulmonary fibrosis, PF)禹于纤维增殖性疾病的范畴,是多种原因所致的间质性肺疾病(interstitial lung disease,ILD)共有的病理基础过程,其病变主要累及肺间质,也可累及肺泡上皮细胞及肺血管,以肺成纤维细胞的异常增生和胶原蛋白为主的细胞外基质过度沉积为主要表现,至今发病机制不明,且没有理想的治疗方法。由于大多数肺部疾病最终转归为肺纤维化,并且随着污染、环境恶化等因素,肺纤维化当今在全球的发病率呈不断上升的趋势,已成为严峻的健康问题,因此对肺纤维化发生机制和有效药物的研究具有非常重要的科学价值。研究显示转化生长因子-β1(transforming growth factor-β1, TGF-β1)是致纤维化关键性的细胞因子,Smads通路介导的致纤维化作用与ERK通路介导的促增殖作用在纤维化的发生发展中均是不可或缺的。肺纤维化属中医“肺痿”、“肺痹”等范畴,其病机为气虚血瘀,故益气活血法是治疗肺纤维化的基本大法。我们在前期对益气活血法干预肺纤维化的研究中发现：补阳还五汤具有抑制实验性肺纤维化大鼠肺组织TGF-β1的过度表达,减少肺组织中羟脯氨酸含量,降低肺泡巨噬细胞肿瘤坏死因子含量的作用,提示补阳还五汤干预肺纤维化的作用可能与其调控TGF-β/Smad/ERK信号通路有关。基于此,我们以TGF-β/Smad/ERK信号通路为切入点,将研究靶点精准定位于肺纤维化形成的关键病理环节,探讨补阳还五汤拮抗肺纤维化的可能作用机制,以期拓展补阳还五汤的适用范围,为临床研究奠定基础。
本研究以博莱霉素(bleomycetin, BLM)诱导肺纤维化大鼠模型为评价载体,从病理学、分子生物学角度探讨补阳还五汤调控TGF-β/Smad/ERK信号通路的作用机制。实验共分为四部分：
1.补阳还五汤对博莱霉素所致肺纤维化大鼠肺指数及肺组织形态学的影响
建立肺纤维化大鼠模型,通过补阳还五汤干预后,动态观察模型大鼠的一般情况(精神、摄食、毛色、活动、体重等)、肺指数,采集肺组织行HE染色和Masson染色,分析病肺组织肺泡炎及肺纤维化程度,探讨补阳还五汤抗肺纤维化的作用。
结果：①-般情况：假手术组大鼠皮毛光泽,行动灵活,反应敏捷,食量正常；模型组大鼠食欲下降,毛发凌乱、稀疏、部分脱毛严重,对外界刺激反应慢、行动迟缓,体重增长缓慢；其余各给药组随实验时间的推进,活动减少、食量下降等症状有不同程度的改善,体重逐渐增加；②肺指数：与假手术相比,模型组大鼠各时间点肺指数增加明显⑦<0.01)；与模型组比较,各给药组大鼠肺指数有不同程度的下降(矿0.01)：与强的松对照组相比,补阳还五汤中剂量组第14d、28d、低剂量组第28d肺指数降低较明显p<0.05)；高剂量组三个时间点肺指数均高于强的松对照组,但与同期模型组相比仍较有明显的降低。③病理形态学：与假手术相比,模型组及各给药组大鼠可见肺泡结构有不同程度的破坏,肺间质增生,有炎细胞漫润和胶原纤维增生形成；与模型组相比,给药组各时间点的肺泡炎和肺纤维化程度均有不同程度的改善p<0.01);其中补阳还五汤中剂量组在中后期降低肺泡炎及纤维化程度方面明显优于同期强的松对照组p<0.05)。
结论：博莱霉素诱导肺纤维化大鼠模型制备成功；补阳还五汤能够较好地控制模型大鼠肺指数的增长,抑制早期的肺泡炎和中后期的肺纤维化。
2.补阳还五汤对博莱霉素所致肺纤维化大鼠血清纤维化指标PCⅢ、Ⅳ-C、HA、LN含量的影响
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用放免法检测各组大鼠血清纤维化指标PCⅢ、Ⅳ-C、HA、LN的含量,验证补阳还五汤对肺纤维化的治疗作用。
结果：①与假手术组相比,其它各组大鼠血清PCⅢ、Ⅳ-C、HA、LN的含量均逐渐升高,以模型组最为明显p<0.01)；②与模型组相比,各给药组大鼠血清PCⅢ、Ⅳ-C、HA、LN含量均有不同程度降低p<0.01);③与强的松对照组相比,补阳还五汤中剂量组第14d、28d以及补阳还五汤低剂量组第28d时,PCⅢ, Ⅳ-C、HA、LN含量下降明显p<0.05)。
结论：经补阳还五汤治疗后的模型大鼠血清纤维化指标含量有所下降,提示补阳还五汤可以有效抑制病肺组织中胶原纤维的增殖以及细胞外基质的沉积,起到较好的抗肺纤维化作用。
3.补阳还五汤调控肺纤维化TGF-β1/Smad通路机制研究
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用免疫组化染色法(S-P法)检测不同时间点各组大鼠肺组织Col-Ⅰ、TPRⅠ、TpRⅡ、Smad3、Smad7的表达,逆转录聚合酶链反应(RT-PCR法)检测肺组织TGF-β1、Smad3、Smad7mRNA的含量,探讨补阳还五汤通过调控TGF-β1/Smad信号通路干预肺纤维化的作用机制。
结果：①与假手术组相比,模型组大鼠肺组织Col-Ⅰ、TβPⅠ、TβRⅡ TGF-β1mRNA、Smad3mRNA表达水平明显上升,差异有统计学意义(p<0.01)；Smad7、Smad7mRNA表达下降(p＜0.01)；②与模型组相比,各给药组Col-Ⅰ、TβRⅠ、 TβRⅡ、TGF-β1mRNA、Smad3mRNA有不同程度的下降(p<0.01or p<0.05);Smad7? Smad7mRNA表达增高(p<0.01or p<0.05);③与强的松对照组相比,补阳还五汤中、低剂量组肺内Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA的表达降低(p<0.01or p<0.05), Smad7、Smad7mRNA的表达增高(p<0.05)。
结论：补阳还五汤能够有效抑制TGF-β1/Smad信号通路中发挥效应的Col-Ⅰ、 TPRⅠ、TPRⅡ、TGF-β1、Smad3等因子的高表达,同时促进该通路中发挥负性调控效应的Smad7达增加,证实了补阳还五汤能够发挥较好的抗肺纤维化作用与其调控TGF-β1/Smad信号通路有关。
4.补阳还五汤调控肺纤维化TGF-β1/ERK通路机制研究
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用Western blot法检测不同时间点各组大鼠肺组织TGF-β1、ERK1/2、p-ERK的表达,探讨补阳还五汤通过调控TGF-β1/ERK通路干预肺纤维化的作用机制。
结果：①与假手术组相比,模型组大鼠肺组织TGF-β1、ERK1/2、p-ERK表达水平明显增高,差异有统计学意义(p<0.01)；②与模型组相比,各给药组TGF-β1、ERK1/2、p-ERK有不同程度的下降,差异明显(p<0.01or p<0.05)；③与强的松对照组相比,补阳还五汤中剂量组在第14d、28d,低剂量组在第28d时TGF-β1、ERK1/2、p-ERK的表达明显降低(p<0.05)。
结论：补阳还五汤可以有效抑制病肺组织TGF-β1、ERK1/2、p-ERK表达上调,提示补阳还五汤能够较好的调控肺纤维化中TGF-β1介导的ERK通路,进而抑制其产生的促增殖作用。
综上所述,本研究采用博莱霉素气管滴注经典造模方法制备大鼠肺纤维化模型,以TGF-β/Smad/ERK信号通路为切入点,采用现代分子生物学等研究技术和手段,从动物水平探讨补阳还五汤干预肺纤维化的可能作用机制。研究结果表明：补阳还五汤可以有效改善模型大鼠肺泡炎症及肺纤维化程度,降低血清PCⅢ、 Ⅳ-C、HA、LN含量,抑制TβRⅠ、TβRⅡ、Smad3、CollagenⅠ、TGF-β1mRNA、 Smad3mRNA、ERK1/2、p-ERK蛋白在病肺组织中的过度表达,促进Smad7以及Smad7mRNA的活性,提示补阳还五汤可以有效调控TGF-β1/Smad介导的致纤维化作用,以及TGF-β1/ERK通路介导的促增殖作用,进而起到抗纤维化的作用。
Pulmonary fibrosis (PF) is a kind of the disease of fiber hyperplasia as a common pathological basis process of interstitial lung disease (ILD) caused by various reasons, its diseased tissues involve pulmonary interstitium, alveolar epithelial cells and ulmo-nary vascular, characterized with over reproduction of lung fibroblast (LFB) and excess deposition of extracellular matrix (ECM) contained collagen protein. As result of its pathogenesis is not thoroughly clear so far, there is no perfect therapeutic method in clinic. Since most of lung diseases could transform into pulmonary fibrosis as their final outcome, And as the air pollution, environment deterioration and other factors, the incidence rate of PF is increasing constantly in the world, it is becoming a severe threat to human health. Therefore, it is a very important value in scientific to study the pathogenesis of PF and effective medicine to treat this disease. Research shows that transforming growth factor-β1(TGF-β1) is the key cytokine of leading to PF, the effect of causing fibrosis of TGF-β1/Smad signal path-mediated and the effect of promoting proliferation of ERK signal path-mediated are indispensable to the development of PF. PF is under the category of "lung atrophy","lung impediment" in traditional Chinese medicine, its mechanism due mostly to qi deficiency with blood stasis, so we believes that tonifying qi and activating blood is the basically therapeutic method. Our preliminary research on the effect of tonifying qi and activating blood' method on PF found that Buyanghuanwu decoction can efficiently regulate expression levels of TGF-β1in the lung tissues, reduce the hydroxylproline (HYP) in bronchoalveolar lavage fluid (BALF) and tumor necrosis factor-α (TNF-α) content in alveolar macrophage (AM) of pulmonary fibrosis rats, which suggests we inhibitory mechanism of Buyanghuanwu decoction on pulmonary fibrosis could be associated with regulating the TGF-β/Smad/ERK signal path. Based on the above study, we use the key point of TGF-β/Smad/ERK signal path, and make our target of research accurately position in the key pathological links of PF' formation, to discuss the associated mechanism of action of Buyanghuanwu decoction in the pulmonary fibrosis, in order to wide the application range, and lay the foundation for the clinical study.
In this study, we apply BLM to induce the PF model on rats as an appraisal carrier, to explore the mechanism of Buyanghuanwu decoction regulating the TGF-β/Smad/ERK signal path from the perspective of pathology and molecular biology. The experimental research consists of four parts as following:
1. The effects of Buyanghuanwu decoction on lung index and pathomorphology in the lung tissue of PF rats by BLM.
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, though observing general status of PF rats (such as the condition of mental, diet, hair, behavioral activity, and weight, etc), the changes of lung index, to measure alveolar catarrh and pulmonary fibrosis degrees in lung tissue dyed with HE and Masson, discussed the effect of Buyanghuanwu decoction on PF.
Results:①General status:The rats of sham operation group's behavioral activity, glossiness of hair and diet were unchanged; model group had the phenomena of less eating, messy or sparse hair, even hair removal, movement decreasing, slow increase of weight, other medicated groups's general status have different improvements with time, increased gradually weight;②Lung index:at all time points, a significant increase in lung index of model group were higher than that of sham operation group (p<0.01); other medicated groups had different decreases in lung index by comparison with model group (p<0.01); compared with the prednisone group, the lung index of Buyanghuanwu decoction middle-dose group showed an obviously decreased tendency on the14th and28th day (p<0.05), this condition of that in Buyanghuanwu decoction low-dose group on the28th day (p<0.05), Buyanghuanwu decoction high-dose group than in prednisone group the lung index of some high at there time points, but were significantly lower than the same period in the model group.③Pathomorphology:compared with the sham operation group, the model group and each medicated groups were mainly featured with destroyed alveoli, thickened alveoli septum and the deposition of collagen fibers on different level; the medicated groups could improve the alveolar catarrh and pulmonary fibrosis on pathomorphology in varying degree by comparison with the model group (p<0.01); the effect of reducing alveolar catarrh and pulmonary fibrosis of Buyanghuanwu decoction middle-dose group had an advantage over that of the prednisone group on the14th and28th day (p<0.05).
Conclusion:The PF rat model induced by BLM was successfully duplicated; Buyanghuanwu decoction could obviously control the growth of lung index, and alleviate alveolar catarrh and pulmonary fibrosis.
2. The effects of Buyanghuanwu decoction on fibrosis index (PCⅢ、Ⅳ-C、HA、 LN) in blood serum of PF rats by BLM.
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction.At different points in time, tested the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum of experimental rats by radioimmanoassay (RIA) method, to prove the therapeutic effect of Buyanghuanwu decoction on PF.
Results:①Compared with the sham operation group, the contents of PCⅢ、 IV-C、HA、LN in blood serum of other groups were gradually increased, and that of the model group was the most obvious (p<0.01);②Each medicated group had different decreases in the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum by comparison with model group (p<0.01);③Compared with the prednisone group, the contents of PCⅢ、Ⅳ-C、HA、LN of Buyanghuanwu decoction middle-dose group obviously decreased on the14th and28th day (p<0.05), as well as that of Buyanghuanwu decoction low-dose group on the28th day (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively reduce the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum of experimental rats by BLM, which proved that buyanghuanwu decoction could effectively control the reproduction of collagen fibers and excess deposition of ECM in lung tissue of PF, and played an anti-fibrosis effect.
3. Research on the mechanism of regulation of Buyanghuanwu decoction in PF based on TGF-β1/Smad signal path
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, tested the expressions of Col-1、TβRⅠ、TβRⅡ、Smad3、Smad7in lung tissue by immunohistochemical staining, measured the contents of TGF-β1、Smad3、Smad7mRNA in lung tissue by reverse transcription polymerase chain reaction (RT-PCR), to discuss the Buyanghuanwu decoction's mechanism of anti-lung fibrosis though regulating TGF-β1/Smad signal path.
Results:①Compared with the sham operation group, the expressions of Col-Ⅰ、 TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA in lung tissue of model group were obviously increased (p<0.01); the expressions of Smad7、Smad7mRNA were gradually decreased (p<0.01);②Each medicated group had different decreases in the expressions of Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA in lung tissue by comparison with model group (p<0.01or p<0.05), the expressions of Smad7、 Smad7mRNA of medicated groups had different increases (p<0.01or p<0.05);③The expressions of Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA Smad3mRNA of buyanghuanwu decoction were lower than that of the prednisone group (p<0.01or p<0.05); on the contrary, the expressions of Smad7、Smad7mRNA showed a increased tendency,, with statistical significance (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively regulate the cell factors' expression levels of exerting effect in TGF-β1/Smad signal path, those were Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1、Smad3, meanwhile promote the expressions of Smad7,which played an opposite role to regulate the signal path, which proved that the therapeutic effect of Buyanghuanwu decoction in PF were associated with regulating the TGF-β/Smad signal path.
4. Research on the mechanism of regulation of Buyanghuanwu decoction in PF based on TGF-β1/ERK signal path
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, tested the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue by Western blot method, to discuss the Buyanghuanwu decoction's mechanism of anti-lung fibrosis though regulating TGF-β1/ERK signal path.
Results:①Compared with the sham operation group, the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue of model group were significantly increased (p<0.01);②Each medicated group had different decreases in the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue by comparison with model group (p<0.01or p<0.05);③Compared with the prednisone group, the expressions of TGF-β1、 ERK1/2、p-ERK of Buyanghuanwu decoction middle-dose group obviously decreased on the14th and28th day (p<0.05),as well as that of Buyanghuanwu decoction low-dose group on the28th day (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively suppress the excess expressions of TGF-β1、ERK1/2、p-ERK, which proved that Buyanghuanwu decoction could regulate the expressions of the key cell factors in TGF-β1/ERK signal path, and had a good effect of controlling proliferation.
In conclusion, we established animal model of PF by a classic method though tracheofistulization with BLM, based on TGF-β/Smad/ERK signal path, to describe the effect and mechanism of Buyanghuanwu decoction on PF from integral level using the methods and techniques of molecular biology. The results prove that Buyanghuanwu decoction could obviously alleviate alveolar catarrh and pulmonary fibrosis in lung tissue of experimental rats by BLM, reduce the contents of PCⅢ Ⅳ-C、HA、LN in blood serum,suppress the excess expressions of Col-Ⅰ、TβRⅠ、 TβRⅡ、TGF-β1、Smad3、ERK1/2、p-ERK,meanwhile promote the viabilities of Smad7, which proved that Buyanghuanwu decoction could efficiently regulate the effect of causing fibrosis of TGF-β1/Smad signal path-mediated and the effect of promoting proliferation of ERK signal path-mediated, and had a good effect of anti-lung fibrosis.
本研究以博莱霉素(bleomycetin, BLM)诱导肺纤维化大鼠模型为评价载体,从病理学、分子生物学角度探讨补阳还五汤调控TGF-β/Smad/ERK信号通路的作用机制。实验共分为四部分：
1.补阳还五汤对博莱霉素所致肺纤维化大鼠肺指数及肺组织形态学的影响
建立肺纤维化大鼠模型,通过补阳还五汤干预后,动态观察模型大鼠的一般情况(精神、摄食、毛色、活动、体重等)、肺指数,采集肺组织行HE染色和Masson染色,分析病肺组织肺泡炎及肺纤维化程度,探讨补阳还五汤抗肺纤维化的作用。
结果：①-般情况：假手术组大鼠皮毛光泽,行动灵活,反应敏捷,食量正常；模型组大鼠食欲下降,毛发凌乱、稀疏、部分脱毛严重,对外界刺激反应慢、行动迟缓,体重增长缓慢；其余各给药组随实验时间的推进,活动减少、食量下降等症状有不同程度的改善,体重逐渐增加；②肺指数：与假手术相比,模型组大鼠各时间点肺指数增加明显⑦<0.01)；与模型组比较,各给药组大鼠肺指数有不同程度的下降(矿0.01)：与强的松对照组相比,补阳还五汤中剂量组第14d、28d、低剂量组第28d肺指数降低较明显p<0.05)；高剂量组三个时间点肺指数均高于强的松对照组,但与同期模型组相比仍较有明显的降低。③病理形态学：与假手术相比,模型组及各给药组大鼠可见肺泡结构有不同程度的破坏,肺间质增生,有炎细胞漫润和胶原纤维增生形成；与模型组相比,给药组各时间点的肺泡炎和肺纤维化程度均有不同程度的改善p<0.01);其中补阳还五汤中剂量组在中后期降低肺泡炎及纤维化程度方面明显优于同期强的松对照组p<0.05)。
结论：博莱霉素诱导肺纤维化大鼠模型制备成功；补阳还五汤能够较好地控制模型大鼠肺指数的增长,抑制早期的肺泡炎和中后期的肺纤维化。
2.补阳还五汤对博莱霉素所致肺纤维化大鼠血清纤维化指标PCⅢ、Ⅳ-C、HA、LN含量的影响
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用放免法检测各组大鼠血清纤维化指标PCⅢ、Ⅳ-C、HA、LN的含量,验证补阳还五汤对肺纤维化的治疗作用。
结果：①与假手术组相比,其它各组大鼠血清PCⅢ、Ⅳ-C、HA、LN的含量均逐渐升高,以模型组最为明显p<0.01)；②与模型组相比,各给药组大鼠血清PCⅢ、Ⅳ-C、HA、LN含量均有不同程度降低p<0.01);③与强的松对照组相比,补阳还五汤中剂量组第14d、28d以及补阳还五汤低剂量组第28d时,PCⅢ, Ⅳ-C、HA、LN含量下降明显p<0.05)。
结论：经补阳还五汤治疗后的模型大鼠血清纤维化指标含量有所下降,提示补阳还五汤可以有效抑制病肺组织中胶原纤维的增殖以及细胞外基质的沉积,起到较好的抗肺纤维化作用。
3.补阳还五汤调控肺纤维化TGF-β1/Smad通路机制研究
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用免疫组化染色法(S-P法)检测不同时间点各组大鼠肺组织Col-Ⅰ、TPRⅠ、TpRⅡ、Smad3、Smad7的表达,逆转录聚合酶链反应(RT-PCR法)检测肺组织TGF-β1、Smad3、Smad7mRNA的含量,探讨补阳还五汤通过调控TGF-β1/Smad信号通路干预肺纤维化的作用机制。
结果：①与假手术组相比,模型组大鼠肺组织Col-Ⅰ、TβPⅠ、TβRⅡ TGF-β1mRNA、Smad3mRNA表达水平明显上升,差异有统计学意义(p<0.01)；Smad7、Smad7mRNA表达下降(p＜0.01)；②与模型组相比,各给药组Col-Ⅰ、TβRⅠ、 TβRⅡ、TGF-β1mRNA、Smad3mRNA有不同程度的下降(p<0.01or p<0.05);Smad7? Smad7mRNA表达增高(p<0.01or p<0.05);③与强的松对照组相比,补阳还五汤中、低剂量组肺内Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA的表达降低(p<0.01or p<0.05), Smad7、Smad7mRNA的表达增高(p<0.05)。
结论：补阳还五汤能够有效抑制TGF-β1/Smad信号通路中发挥效应的Col-Ⅰ、 TPRⅠ、TPRⅡ、TGF-β1、Smad3等因子的高表达,同时促进该通路中发挥负性调控效应的Smad7达增加,证实了补阳还五汤能够发挥较好的抗肺纤维化作用与其调控TGF-β1/Smad信号通路有关。
4.补阳还五汤调控肺纤维化TGF-β1/ERK通路机制研究
建立肺纤维化大鼠模型,通过补阳还五汤干预后,采用Western blot法检测不同时间点各组大鼠肺组织TGF-β1、ERK1/2、p-ERK的表达,探讨补阳还五汤通过调控TGF-β1/ERK通路干预肺纤维化的作用机制。
结果：①与假手术组相比,模型组大鼠肺组织TGF-β1、ERK1/2、p-ERK表达水平明显增高,差异有统计学意义(p<0.01)；②与模型组相比,各给药组TGF-β1、ERK1/2、p-ERK有不同程度的下降,差异明显(p<0.01or p<0.05)；③与强的松对照组相比,补阳还五汤中剂量组在第14d、28d,低剂量组在第28d时TGF-β1、ERK1/2、p-ERK的表达明显降低(p<0.05)。
结论：补阳还五汤可以有效抑制病肺组织TGF-β1、ERK1/2、p-ERK表达上调,提示补阳还五汤能够较好的调控肺纤维化中TGF-β1介导的ERK通路,进而抑制其产生的促增殖作用。
综上所述,本研究采用博莱霉素气管滴注经典造模方法制备大鼠肺纤维化模型,以TGF-β/Smad/ERK信号通路为切入点,采用现代分子生物学等研究技术和手段,从动物水平探讨补阳还五汤干预肺纤维化的可能作用机制。研究结果表明：补阳还五汤可以有效改善模型大鼠肺泡炎症及肺纤维化程度,降低血清PCⅢ、 Ⅳ-C、HA、LN含量,抑制TβRⅠ、TβRⅡ、Smad3、CollagenⅠ、TGF-β1mRNA、 Smad3mRNA、ERK1/2、p-ERK蛋白在病肺组织中的过度表达,促进Smad7以及Smad7mRNA的活性,提示补阳还五汤可以有效调控TGF-β1/Smad介导的致纤维化作用,以及TGF-β1/ERK通路介导的促增殖作用,进而起到抗纤维化的作用。
Pulmonary fibrosis (PF) is a kind of the disease of fiber hyperplasia as a common pathological basis process of interstitial lung disease (ILD) caused by various reasons, its diseased tissues involve pulmonary interstitium, alveolar epithelial cells and ulmo-nary vascular, characterized with over reproduction of lung fibroblast (LFB) and excess deposition of extracellular matrix (ECM) contained collagen protein. As result of its pathogenesis is not thoroughly clear so far, there is no perfect therapeutic method in clinic. Since most of lung diseases could transform into pulmonary fibrosis as their final outcome, And as the air pollution, environment deterioration and other factors, the incidence rate of PF is increasing constantly in the world, it is becoming a severe threat to human health. Therefore, it is a very important value in scientific to study the pathogenesis of PF and effective medicine to treat this disease. Research shows that transforming growth factor-β1(TGF-β1) is the key cytokine of leading to PF, the effect of causing fibrosis of TGF-β1/Smad signal path-mediated and the effect of promoting proliferation of ERK signal path-mediated are indispensable to the development of PF. PF is under the category of "lung atrophy","lung impediment" in traditional Chinese medicine, its mechanism due mostly to qi deficiency with blood stasis, so we believes that tonifying qi and activating blood is the basically therapeutic method. Our preliminary research on the effect of tonifying qi and activating blood' method on PF found that Buyanghuanwu decoction can efficiently regulate expression levels of TGF-β1in the lung tissues, reduce the hydroxylproline (HYP) in bronchoalveolar lavage fluid (BALF) and tumor necrosis factor-α (TNF-α) content in alveolar macrophage (AM) of pulmonary fibrosis rats, which suggests we inhibitory mechanism of Buyanghuanwu decoction on pulmonary fibrosis could be associated with regulating the TGF-β/Smad/ERK signal path. Based on the above study, we use the key point of TGF-β/Smad/ERK signal path, and make our target of research accurately position in the key pathological links of PF' formation, to discuss the associated mechanism of action of Buyanghuanwu decoction in the pulmonary fibrosis, in order to wide the application range, and lay the foundation for the clinical study.
In this study, we apply BLM to induce the PF model on rats as an appraisal carrier, to explore the mechanism of Buyanghuanwu decoction regulating the TGF-β/Smad/ERK signal path from the perspective of pathology and molecular biology. The experimental research consists of four parts as following:
1. The effects of Buyanghuanwu decoction on lung index and pathomorphology in the lung tissue of PF rats by BLM.
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, though observing general status of PF rats (such as the condition of mental, diet, hair, behavioral activity, and weight, etc), the changes of lung index, to measure alveolar catarrh and pulmonary fibrosis degrees in lung tissue dyed with HE and Masson, discussed the effect of Buyanghuanwu decoction on PF.
Results:①General status:The rats of sham operation group's behavioral activity, glossiness of hair and diet were unchanged; model group had the phenomena of less eating, messy or sparse hair, even hair removal, movement decreasing, slow increase of weight, other medicated groups's general status have different improvements with time, increased gradually weight;②Lung index:at all time points, a significant increase in lung index of model group were higher than that of sham operation group (p<0.01); other medicated groups had different decreases in lung index by comparison with model group (p<0.01); compared with the prednisone group, the lung index of Buyanghuanwu decoction middle-dose group showed an obviously decreased tendency on the14th and28th day (p<0.05), this condition of that in Buyanghuanwu decoction low-dose group on the28th day (p<0.05), Buyanghuanwu decoction high-dose group than in prednisone group the lung index of some high at there time points, but were significantly lower than the same period in the model group.③Pathomorphology:compared with the sham operation group, the model group and each medicated groups were mainly featured with destroyed alveoli, thickened alveoli septum and the deposition of collagen fibers on different level; the medicated groups could improve the alveolar catarrh and pulmonary fibrosis on pathomorphology in varying degree by comparison with the model group (p<0.01); the effect of reducing alveolar catarrh and pulmonary fibrosis of Buyanghuanwu decoction middle-dose group had an advantage over that of the prednisone group on the14th and28th day (p<0.05).
Conclusion:The PF rat model induced by BLM was successfully duplicated; Buyanghuanwu decoction could obviously control the growth of lung index, and alleviate alveolar catarrh and pulmonary fibrosis.
2. The effects of Buyanghuanwu decoction on fibrosis index (PCⅢ、Ⅳ-C、HA、 LN) in blood serum of PF rats by BLM.
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction.At different points in time, tested the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum of experimental rats by radioimmanoassay (RIA) method, to prove the therapeutic effect of Buyanghuanwu decoction on PF.
Results:①Compared with the sham operation group, the contents of PCⅢ、 IV-C、HA、LN in blood serum of other groups were gradually increased, and that of the model group was the most obvious (p<0.01);②Each medicated group had different decreases in the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum by comparison with model group (p<0.01);③Compared with the prednisone group, the contents of PCⅢ、Ⅳ-C、HA、LN of Buyanghuanwu decoction middle-dose group obviously decreased on the14th and28th day (p<0.05), as well as that of Buyanghuanwu decoction low-dose group on the28th day (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively reduce the contents of PCⅢ、Ⅳ-C、HA、LN in blood serum of experimental rats by BLM, which proved that buyanghuanwu decoction could effectively control the reproduction of collagen fibers and excess deposition of ECM in lung tissue of PF, and played an anti-fibrosis effect.
3. Research on the mechanism of regulation of Buyanghuanwu decoction in PF based on TGF-β1/Smad signal path
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, tested the expressions of Col-1、TβRⅠ、TβRⅡ、Smad3、Smad7in lung tissue by immunohistochemical staining, measured the contents of TGF-β1、Smad3、Smad7mRNA in lung tissue by reverse transcription polymerase chain reaction (RT-PCR), to discuss the Buyanghuanwu decoction's mechanism of anti-lung fibrosis though regulating TGF-β1/Smad signal path.
Results:①Compared with the sham operation group, the expressions of Col-Ⅰ、 TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA in lung tissue of model group were obviously increased (p<0.01); the expressions of Smad7、Smad7mRNA were gradually decreased (p<0.01);②Each medicated group had different decreases in the expressions of Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA、Smad3mRNA in lung tissue by comparison with model group (p<0.01or p<0.05), the expressions of Smad7、 Smad7mRNA of medicated groups had different increases (p<0.01or p<0.05);③The expressions of Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1mRNA Smad3mRNA of buyanghuanwu decoction were lower than that of the prednisone group (p<0.01or p<0.05); on the contrary, the expressions of Smad7、Smad7mRNA showed a increased tendency,, with statistical significance (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively regulate the cell factors' expression levels of exerting effect in TGF-β1/Smad signal path, those were Col-Ⅰ、TβRⅠ、TβRⅡ、TGF-β1、Smad3, meanwhile promote the expressions of Smad7,which played an opposite role to regulate the signal path, which proved that the therapeutic effect of Buyanghuanwu decoction in PF were associated with regulating the TGF-β/Smad signal path.
4. Research on the mechanism of regulation of Buyanghuanwu decoction in PF based on TGF-β1/ERK signal path
Established PF model rats, on the second day after the models were successfully made, treated with Buyanghuanwu decoction. At different points in time, tested the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue by Western blot method, to discuss the Buyanghuanwu decoction's mechanism of anti-lung fibrosis though regulating TGF-β1/ERK signal path.
Results:①Compared with the sham operation group, the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue of model group were significantly increased (p<0.01);②Each medicated group had different decreases in the expressions of TGF-β1、ERK1/2、p-ERK in lung tissue by comparison with model group (p<0.01or p<0.05);③Compared with the prednisone group, the expressions of TGF-β1、 ERK1/2、p-ERK of Buyanghuanwu decoction middle-dose group obviously decreased on the14th and28th day (p<0.05),as well as that of Buyanghuanwu decoction low-dose group on the28th day (p<0.05).
Conclusion:Buyanghuanwu decoction could effectively suppress the excess expressions of TGF-β1、ERK1/2、p-ERK, which proved that Buyanghuanwu decoction could regulate the expressions of the key cell factors in TGF-β1/ERK signal path, and had a good effect of controlling proliferation.
In conclusion, we established animal model of PF by a classic method though tracheofistulization with BLM, based on TGF-β/Smad/ERK signal path, to describe the effect and mechanism of Buyanghuanwu decoction on PF from integral level using the methods and techniques of molecular biology. The results prove that Buyanghuanwu decoction could obviously alleviate alveolar catarrh and pulmonary fibrosis in lung tissue of experimental rats by BLM, reduce the contents of PCⅢ Ⅳ-C、HA、LN in blood serum,suppress the excess expressions of Col-Ⅰ、TβRⅠ、 TβRⅡ、TGF-β1、Smad3、ERK1/2、p-ERK,meanwhile promote the viabilities of Smad7, which proved that Buyanghuanwu decoction could efficiently regulate the effect of causing fibrosis of TGF-β1/Smad signal path-mediated and the effect of promoting proliferation of ERK signal path-mediated, and had a good effect of anti-lung fibrosis.
引文
[1]Ask K, Martin GE, Kolb M, Gauldie J.Targeting genes for treatment in idiopathic pulmonary fibrosis:challenges and opportunities, promises and pitfalls.Proc Am Thorac Soc.2006,3(4):389-93
[2]陆再英,钟南山.内科学(第7版)[M].北京：人民卫生出版社,2008；10：101
[3]张丽.肺纤维化的治疗现状及展望[J].肿瘤预防与治疗,2009,22(1)：100-103
[4]Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis:impact of oxygen and colchicines, prednisone, or no therapy on survival. AmJ Respir Crit Care Med, 2000,161:1172-1178
[5]K A sk, G E M. Martin, M. Kolb, et al. Targeting genes for treatment in idiopathic pu-lmonary fibrosis [J]. Proc Am Tho rac Soc,2006,3:389-393
[6]Tashkin D P, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cycloph-osphamide on out comes at 2 years in scleroderma a lung disease [J]. Am J Respir Crit Care Med,2007,176:1026-1034
[7]Meurer S K, Tihaa L, Lahme B, et al. Identification of endoglin in rat hepatic stellate cells:new insights into transforming growth factor beta receptor signaling. J Biol Chem, 2005,280(4):3078-3087
[8]Isaka Y, Tsnjie M, Asado Y, et al. Transforming growth factor-beta 1 antisense oligo-deoxy-nucleotides block interstitial fbrosis in un ilateral ureteral obstruction. Kidney Int, 2000,58(5):1885-1892
[9]Ten Dijke P,I-I511 CS. New insights into TGF-beta/Smad signaling. Trends Biochem Sci,2004,29(5):265-273
[10]Park SH. Fine tuning and cross-talking of TGF-beta singal by inhibitory smads. J Biochem Mol Biol,2005,38(1):9-16
[11]Hasegawa T, Nakao A, Sumiyoshi K, et al. SB2431542 Inhibits T-GF-β-induced contraction of collagen gel by normal and keloid fibroblasts.J Dermatol Sci,2005,39(1): 33-38
[12]Huang M, Sharma S, Zhu L X, et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis [J]. Clin Invest,2002,109(7):931-937
[13]Kamaraju A K,Roberts A B. Role ofRho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carciuoma cells in vivo. J Biol Chem,2005,280(2):1024-1036
[14]Bonniaud P, Margetts PJ, Kolb M, et al.Transient transgene expression of CTGF in the lung induces mode-rate and reversible fibrosis. Eur Respir J,2002,20(38):378-389
[15]Flanders KC. Smad3 as a mediator of the fibrotic response. International Journal of Experimental Pathology,2004,85(2):47-64
[16]Nakao A, Fnjii M, Matsumura R'et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lun g fibrosis in mice [J]. Clha Invest,1999,104(1): 5-11
[17]GaoJ, LiuPQ. Connectivet issue growth factor and its role in cardio vascular disease [J]. MedRecap,2006,12(20):1219-1221
[18]Secker G A, Shot A J, Sampson E, et al.TGF beta stimulated reepithelialisation is regulated by CTGF and Ras/MEK/ERK signaling[J].Exp Cell Res,2008,314(1):131-42
[19]黄长海,杨敏,李惊自,等.结缔组织生长因子通过活化ERK1/2信号通路促成纤维细胞生成[J].中华医学杂志,2005,85：1322-1327
[20]Kim C S, Kim J M, Nam S Y, et al. Low-dose of ionizing radiation enhances cell pr-oliferation via transient ERK1/2 and p38 activation in normal human lung fibroblasts. J Radiat Res,2007,48(5):407-415
[21]Riser BL, Denichilo M, ConesP, etal.Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression diabetic glomerulosclerosis[J]. Jam Soc Nephrol,2000,11(1):25-38
[22]杨雅茹,黄艳,李俊.TGF-pl介导的Smads与ERK通路在肺纤维化中的作用及相互关系[J].中国药理学通报,2010,26(5)：561-563
[23]Stroschein S L, Wang W, LuoKX.Cooperative binding of Smad proteins to two adja-cent DNA elements in the plasminogen activator in hibitor-1 promoter mediates transfor-ming growth factorβ-induced smad-dependent transcriptional activation[J].J Biol Chem, 1999,274(14):9431-41
[24]TaoY Y, Wang X L, LiuCH. Salvianolic acid-B effects on TGF-B1/ERK signaling transducfion in NIH/3T3 fibroblast[J]. J Cap Med Univ,2007,28(2):192-195
[25]俞新,杨继兵.肺纤维化中医药研究进展[J].中华现代中医学杂志,2010,6(1)：14-16
[26]杨瑶,潘强,王世岭,等.中药治疗肺纤维化的研究进展[J].中国药业,2004,13(8)：21-24
[27]黄霞,袁效涵,等.肺纤维化病因学及中医药实验研究现状[J].辽宁中医杂志,2008,35(12)：1946-1949
[28]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP-22和TIMP-1表达的影响[J]华中科技大学学报·医学版,2006,36(1)：35-56
[29]盛丽,姚岚,王丽,等.水蛭、地龙抗实验性小鼠肺纤维化作用的研究[J].中医研究,2006,09(2)：15-17
[30]葛敏,戴令娟.川芎丹参提取液对大鼠肺纤维化的影响研究[J].实用临床医药杂志,2006,10(5)：75-77
[31]柴文戍,于镜泊,李永春.当归对肺纤维化大鼠肺形态学及胶原的影响[J].中国全科医学,2004,7(8)：531-533
[32]刘玉庆,李谈,等.益气活血方对肺纤维化黏附分子表达影响的实验研究[J].天津中医药,2009,26(1)：54-56
[33]孙增涛,封继宏,等.益气活血散结法对肺纤维化的干预效果及机制研究[J].天津中医药大学学报,2008,27(3)：209-212
[34]翟华强,杨毅,等.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893
[35]Noble PW, Homer RJ. Idiopathic pulmonary fibrosis:new insights into pathogenesis. Clin Chest Med.2004,25(4):749-58, vii. Review
[36]Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta 1:potential role in idiopathic pulmonary fibrosis. Am J Pathol,2005,166(5):1321
[37]Bhatt N, Baran CP, Allen J, Magro C, Marsh CB.Promising pharmacologic innovations in treating pulmonary fibrosis. Current Opinion in Pharmacology,2006,6: 284-92
[38]Szapiel S V, Elson Na, Fulmer J D, et al. Bleomycin induced interstitial pulmonary disease in the nude, athymic mouse [J]. Am Rev Respir Dis,1979,120:893-9
[39]Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol,2005,32:342-9
[40]Barbarin V, Xing Z, Delos M, Lison D, Huaux F. Pulmonary over expression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol,2005,288 (5):L841-L848
[41]刘干,李俊,高建,等.肺纤维化模型研究进展[J].安徽医药,2012,14(10)：1117-20
[42]左竹林,段生会.百草枯中毒和百草枯肺[J].中国临床医生,2000,28(8)：22
[43]Card JW, Racz WJ, Brien JF,et al. Differential effects of pirfenidone on acute pulmo-nary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity[J]. Toxicological Sciences,2003,75:169-180
[44]王世鑫.二氧化硅粉尘致肺纤维化机制及早期生物标记物研究[D].重庆大学博士论文,2004,10
[45]胡晓玲.免疫复合物致大鼠肺间质纤维化作用的研究[J].青岛大学医学院学报,2004,40(2)：112-116
[46]孔琪,秦川.SARS市纤维化发病机制的比较医学研究[J].中国比较医学杂志,2005,15(6)：335-338
[47]韩光,周云峰,彭敏,等.小鼠放射性肺损伤模型的建立与鉴定[J].中华放射医学与防护杂志,2006,26(5)：442-4
[48]GEISER T. Idiopathic pulmonary fibrosism disorder of alveolar wound repair[J]. Swiss Med Wkly,2003,133(29-30):405-411
[49]Felix C, Jack G, Geofrey J. Pulmonary fibrosis searching for model answers[J]. Am J Respir Cell Mol Biol,2005,33:9-13
[50]SniderGL, CelliBR, GoldsteinRH, et al. Chronic interstitial pulmonary fibrosis prod-uced in hamsters by endotrachel bleomyein. Am Rev Res Pir Dis 1978,117:289-297
[51]Manoury B, NenanS, Guenonl, et al. Maero Phage metalloelastase(MMP-12) defic-iency does not alter bleomycin-induced Pulmonary fibrosis in mice. J Inflamm(Lond), 2006,3:2
[52]Gharaee M, Ullenbruch M, Phan SH. Animal models of pulmonary Fibrosis J. Meth-ods Mol Med,2005,117:251-259
[53]蔡颖.肺纤维化的药物治疗进展[J].世界临床药物,2008,29(1)：17-19
[54]Selman M, Thannickal V, Pardo A, et al. Idiopathic pulmonary fibrosis:pathofenes-is and therapeutic approaches. Drugs,2004,64:405-430
[55]崔冰,胡卓伟.抗肺纤维化药物治疗研究进展[J].生理科学进展,2008,39(3)：233-238
[56]魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏系数和肺胶原含量的变化[J].工业卫生与职业病,2001,27(6)：351-353
[57]Xiuxia Zhou, Haizhen Hu, Mai-Lan N. H, et al. Mechanisms of tissue inhibitor of metalloproteinase-1 augmentation by IL-13 on TGF- beta 1- stimulated primary human fibroblasts. J Allergy Clin Immunol,2007,119(6):1388-97
[58]孙旭明,何振华,陈林.肺间质纤维基质重建与肺纤维化的研究进展[J].中国实用医药,2011,6(24)：242-244
[59]郝小惠,张丽,王献华.胶原与肺间质纤维化的研究进展[J].华北煤炭医学院学报,2005,7(1)：43-45
[60]彭丽芬.支气管肺泡灌洗液对特发性肺间质纤维化的诊断价值[J].中国医学研究与临床,2003,1：75
[61]王佑娟,曾莉,吴琴琴,等.特发性肺纤维化患者血中细胞外基质成分的变化及与肺功能指标的关系[J].实用医学杂志,2008,24(21)：3699-70
[62]Van HoozenB E, Grimmer K L, Marelieh G P et al. Early Phase collagen synthesis in lungs of rats exposed to bleomyein[J]. Toxieology,2000,147(1):1-13
[63]周明先.肺结核患者血清纤维化指标测定及意义[J].放射免疫学杂志,2009,19(1)：25-26
[64]王希明,陈学奎.透明质酸与呼吸系统疾病[J].临床肺科杂志,2008,13(9)：1185
[65]Ueki N, Taguehi T, Takahshi M, et al. Inhibition of hyaluronan synthesis by veasnari-none in cultured human myofibroblasts[J]. Biochim Biophys Acta,2000,1495(2):160
[66]牛建昭,责长恩.器官纤维化基础及中医药防治[M].北京：人民卫生出版社,2008：102
[67]杨汀,王辰,庞宝森,等.透明质酸对大鼠肺泡巨噬细胞和肺成纤维细胞分泌蛋白酶的影响[J].中国病理生理杂志,2009,25(3)：541-546
[68]张青竹,郭丽萍.肺结核继发性纤维化指标检测的临床研究[J].实用心脑肺血管病杂志,2011,19(2)：191-193
[69]LaPPi-Blaneo E, Kaarteenaho-Wiik R, Salo S, et al. Laminin-5 gamma2 chain in cry-ptogenic organizing pneumonia and idiopathic pulmonary fibrosisl[J]. Am J Res Pir Crit Care, Med,2004,169(1):27-33
[70]Christopher J A, Juan X C, Sonja H, et al. Mycobacterium tuberculosis produces pili during human infection [J]. PNAS,2007,104(12):5145-50
[71]徐峥嵘.细胞因子及其特异性抑制剂与肺纤维化的治疗[J].中国公共卫生,21(6)：750-753
[72]胡迎春,贺性鹏.层粘连蛋白与肺纤维化病变关系的研究进展[J].医学综述,2010,16(4)：484-486
[73]费雁.芪丹化纤方对大鼠肺纤维化的干预作用及机制研究[D].湖北中医学院博士论文,2009,5：41-42
[74]Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med.2002,166(6):839-42
[75]Bhatt N, Baran CP, Allen J, Magro C, Marsh CB. Promising pharmacologic innovati-ons in treating pulmonary fibrosis. Current Opinion in Pharmacology,2006,6:284-292
[76]Torsten R, Dunkern, Daniel F, Giovanni A. et al. Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activat-ors of soluble guanylyl cyclase.European Journal of Pharmacology,2007,572:12-22
[77]Yun Zhao, Dawn A. Geverd Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis:a negative feedback loop of TGF-β signaling. Biochemical and Biop-hysical Research Communications,2002,294:319-323
[78]Evans R A, Tian Y C, Steadman R, et al. TGF-betal mediated fibroblast-myofibrobl-ast terminal differentiation-the role of Smad proteins. Exp Cell Res.2003,282(2):90-100
[79]Antoniou K M, Pataka A, Bouros D, et al. Pathogenetic pathways and novel pharma- cotherapeutic targets in idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Ther-apeutics.2007,20(5):453-61
[80]Yamamura Y, Hua X, Bergelson S, et al. Critical role of Smads and AP-1 complex in transforming growth factor-beta dependent apoptosis. J BolChem,2000,275(46): 36295-36302
[81]Chen W, Fu XB, Sheng ZY. Review of current progress in the structure and function of Smad protein. Chinese Medical Journal,2002,115(3):446-450
[82]牛建昭,责长恩.器官纤维化基础及中医药防治[M].北京：人民卫生出版社,2008：102
[83]黄顺玲.肝脏靶向性导入TGF-β1isiRNA对急性肝损伤大鼠TGF-p/Smad信号传导通路的影响.中南大学博士论文,2007,5：23
[84]Van Hoozen B E, Grimmer K L, Marelieh G P, et al. Early Phase collagen synthesis in lungs of rats exposed to bleomycin[J]. Toxicology,2000,147(1):1-13
[85]Reiser K M, Hesterberg T W, Hasehek W M, et al. Experimental silicosis:1. Acute ef-fects of intratracheally instilled quartz on collagen metabolism and morphologic characte-ristics of rat lungs. Am J Pathol,1982,107:176-185
[86]马跃文.TGF-β1与其TβRⅠ、TβRⅡ影响博莱霉素致大鼠纤维化肺内胶原Ⅰ、Ⅲ Ⅳ、Ⅴ型沉积的研究[D].中国医科大学博士论文,1997,3：45-46
[87]Cutroneo K R, White S L, Phan S H, et al. Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression [J]. J Cell physiol, 2007,211(3):585-589
[88]Lee C G, Cho S J, Kang M J, et al. Early growth response gene 1 mediated apoptosis is essential for transforming growth factor beta 1-induced pulmonary fibrosis. Exp Med, 2004,200:377-389
[89]Gauldie J, Kolb M, Ask K. Smad3 signaling involved in pulmonary fibrosis and Emphysema. The Proeeedings of the American Thoracic Society,2006,3:696-702
[90]Ask K, Boxuliaud P, Maass K, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoforml but not TGF-beta3. Int. J Biochem Cell BiOl,2008,40:484-495
[91]徐国萍,徐达.TGF-p,诱导的肺泡Ⅱ型上皮细胞向间质细胞转变[J].复旦学报,2007,34(2)：223-227
[92]Alberti A, Sarchielli P, Gallinella E, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome:a Preliminary study[J]. J Sleep Res,2003,12(4):305-311
[93]余维涛,崔社怀,杨雪梅.特异性stealth siRNA抑制小鼠肺成纤维细胞TGF-β1表达的实验研究[J].第三军医大学学报,2007,29(21)：8302
[94]Scotton C J, Chambers R C. Molecular targets in pulmonary fibrosis:the myofibrob-last in focus [J]. Chest,2007,132:1311-1321
[95]Kim K K, Kugler M C, Wolters P J, et al. Alveolar epithelial cell mesenchymal tran-sition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci USA,2006,103:13180-13185
[96]Amanda Goodwin, Gisli Jenkins. Role of integrin-mediated TGF-β activation in the pathogenesis of pulmonary fibrosis[J]. Biochemical Society Transactions,2009,37:849-854
[97]芮炜玮,转化生长因子β1及相关细胞因子在肺纤维化发生中的作用[J].同济大学学报(医学版),2010,31(3)：133-136
[98]Ask K, Boxuliaud P, Maass K, e tal. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Bioehem Cell Bi01.2008,40:484-495
[99]Kenneth R C, Shery L W, Sem H P, et al. Therapies for bleomycin indueed lung fibro-sis through regulation of TGF-β1 induced collagen gene expression. J Cell. Physiol,2007, 211(8):585-589
[100]Massague J. TGF-beta in Cancer. Cell,2008,134(2):215-230
[101]Kohei M, Hiroyuki S, Takeshi M, et al. Imamura Regulation of TGF-βsignaling and its roles in progression of tumor. Cancer,2003,94(3):230-234
[102]Yamamura Y, Hua X, Bergelson S, et al. Critical role of Smads and AP-1 complex in transforming growth factor-beta dependent apoptosis. J Bol Chem,2000,275(46):36295-36302
[103]Chen W, Fu XB,Sheng ZY. Review of current progress in the structure and function of Smad protein. Chinese Medical Journal,2002,115(3):446-450
[104]陈卫花,程慧敏,孔庆兖,等TGF-β信号通路及细胞黏附分子在非小细胞肺癌 的研究[J].徐州医学院学报,2007,27(8)：522-528
[105]Schmierer B, Hill CS. TGF-beta-Smad signal transduction molecular specificity and functional flexibility. Nat Rev Mol Cell Biol,2007,8(12):970-982
[106]Konrad L, Scheiber JA, Volck-Badouin E, et al. Alternative splicing of TGF-betas and their high-affinity receptors T beta R I, T beta R II and Tbeta R III (betaglycan) reveal new Variants in human prostatic cells. RMC Genomics,2007,11(8):318-330
[107]Razzaque M S, Taguchi T. Pulmonary fibrosis:cellular and molecular events. Pathol Int.2003,53(3):133-45
[108]Gail E, Martin M, Kjetil A S K, et al. The transforming growth factor-beta (TGF-β) family and pulmoary fibrosis.Drug Discover Today:Dis Meeh,2006,3:99-103
[109]Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and resistent to TGF-beta-mediated pulmonary fibrosis. J Inmunol.2004,173:2099-2108
[110]Hiroyuki Higashiyama. Receptor-activated Smad localization in Bleomycin-Induced Pulmonary fibrosis. J Clin Pathol Mar 2007,60:283-289
[111]Amle V G, Frederipue L B.Imbalance of Receptor-regulated and Inhibitory Smads in lung fibroblasts from bleomyein exposed rats. Am J Res Pir Cell Mol Biol,2007,36: 206-212
[112]Bonniaud P, MargettsP J, Ask K. TGF-p and Smad3 signaling link inflammation to chronic fibrogenesis. Journal of Immunology,2005,175:5390-5395
[113]Gauldie J, Bonniaud P, Sime P, etal.TGF-beta, Smad3 and the process of Progressive fibrosis. Biochem Soc Trans,2007,35(4):661-664
[114]Flanders K C.Smad3 as a mediator of the fibrotic response. Int J Exp Pathol,2004, 85(2):47-64
[115]Higashiyama H, Yoshimoto D, OkamotoY, et al.Receptor-activated Smad localisa-tion in bleomycin-indueed pulmonary fibrosis. J Clin Pathol,2007,60(3):283-289
[116]Fukasawa H, Yamamoto T, Togawa A. Down-regulation of Smad7 expression by ubiquitindependent degradation contributes to renal fibrosis in obstruetive nephropathy in mice. PNAS.2004,101(23):8687-8692
[117]Galvin K M, Donovan M J, Froneh C A, et al. A role for Smad7 in development and homeostasis of the cardiovascular system. Nat Genet,2000,24(2):171-174
[118]Suzuki C, Murakami G Fukuehi M, et al. Smurfl regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem,2002,277(42):39919 39925
[119]Zhao J, Shi W, Chen H, et al. Smad7 and Smad6 differentially modulate transformi-ing growth factor β-induced inhibition of embryonic lung morphogenesis. J Biol Chem, 2000,275:23992-23997
[120]Nakao A, Okumura K, Ogawa H. Smad7:a new key player in TGF-beta associated disease. Trends Mol Med,2002,8(8):361-363
[121]Huang M, Sharma S, Zhu L X, et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest,2002,109(7):931-937
[122]Venkatesan N, pini L, Ludwig M S. Changes in Smad expression and subcellular localization in bleomycin-indueed pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2004,287:1342-134
[123]高建.当归补血总苷的研制及对实验性肺纤维化的干预作用和分子机制研究[D].2009,6：84
[124]徐芳,徐启勇,叶燕青.ERK信号通路在肺纤维化大鼠中的研究[J].武汉大学学报(医学版),2005(03)：322-325
[125]Ben-David H, Aruna B V, Seger R, et al. A 50-kDaERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses[J]. Proc Natl Acad Sci USA,2006,103(48):18232-18237
[126]杨雅茹,黄艳,李俊.TGF-β1介导的Smads与ERK通路在肺纤维化中的作用及相互关系[J].中国药理学通报,2010,21(5)：561-563
[127]Ranzato E, Patrone M, Pedrazzi M, et al. HMGbl promotes scratch wound closure of HaCaT keratinocytes via ERK1/2 activation[J]. Mol Cell Biochem,2009,332(1-2): 199-205
[128]Ranzato E, Patrone M, Pedrazzi M, et al. Hmgbl promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation[J]. Cell Biochem Biophys, 2010,57(1):9-17
[129]Davis B H, Chen A, Beno D A. Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression[J]. J Biol Chem,1996,271:11039-11042
[130]Mucsi I, Skorecki K L, Goldberg H J. Extracellular signal-regulated kinase and the small GTP-binding protein, rac, contribute to the effects of transforming growth factorpi on gene expression[J].Bid Chem,1996,271:16567-16572
[131]Huang C H, Yang M, Li J Z, et al. Connective tissue growth factor contribute to the growth of myofibroblast by activating ERKI/2 signaling pathway [J]. Chin Med,2005,85: 1322-1327
[132]赵辉平,王胜春,胡咏斌.五灵胶囊对肝纤维化大鼠肝组织TGF-β1/Smad及Ras/ERK信号通路蛋白的影响[J].胃肠病学和肝病学杂志,2009,18(5)：392-396
[133]Hayashide T, Decaestecker M, Schnaper H W. Crosstalk between ERK/MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses ill human mesan-gial ceils[J]. FASEB J,2003,17(11):1576-1578
[134]冯莉,王献华.转化生长因子-p1介导的ERK/MAPK信号通路与肺纤维化[J].中国煤炭工业医学杂志,2008,11(10)：1621-1623
[135]Fubini B, Hubbard A. Reactive oxygen species(ROS)and reactive nitrogen species (RNS)generation by silica in inflammation and fibrosis[J]. Free Radic Biol Med,2003, 34(12):1507-1516
[136]Robledo R F, Buder-Hofmann S A, Cummins A B, at al. Increased phosphorylated extracellular signal regulated kinase immune reactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice[J]. Am J Pathol, 2000,156(4):1307-1316
[137]Kimcs C S, Kim J M, Nam SY, et al. Low-dose of ionizing radiation enhances cell proliferation via transient ERKI/2 and p38 activation in normal human lung fibroblasts. J Radiat Res,2007,48(5):407-415
[1]姚楚芳.中医药防治肺间质纤维化[J].中西医结合学报,2003,1(3)：234-238
[2]陈惠.中西医结合治疗肺间质纤维化的临床进展[J].黑龙江中药,2004,2：63-64
[3]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91
[4]王永炎,晁恩祥主编.今日中医内科[M].北京：人民卫生出版社,2000：309
[5]黄帝内经素问[M].北京：人民卫生出版社,1996：538
[6]张仲景(汉).金匮要略[M].北京：人民卫生出版社,2005：25
[7]巢元方(隋).诸病源候论[M].北京：人民卫生出版社,1956：11
[8]韩学杰主编.孙一奎医学全书[M].北京：中国中医药出版社,1999：174
[9]王肯堂(明).证治准绳[M].北京：人民卫生出版社,1991：145
[10]田代华整理.黄帝内经素问.北京：人民卫生出版社,2005：124
[11]田代华,刘更生整理.灵枢经[M].北京：人民卫生出版社,2005：14
[12]秦景明(明).症因脉治[M].北京：中国中医药出版社,1998：239
[13]陈士铎(清).辨证录[M].北京：中国中医药出版社,1995：55
[14]叶天士(清),临证指南医案[M].上海：上海科技出版社,2000：294
[15]谢观.中华医学大辞典[M].沈阳：辽宁科技出版社,1994：872
[16]孙思邈(唐).千金要方[M].北京：人民卫生出版社,1956：315
[17]喻嘉言(清).医门法律(喻嘉言医学全书)[M].北京：中国中医药出版社,1999：361
[18]巢元方(隋).诸病源候论[M].北京：人民卫生出版社,1956：82
[19]郑洪新主编.周学海医学全书[M].北京：中国中医药出版社,1999：276
[20]清·叶天士.《临证指南医案》[M].北京：人民卫生出版社,2008：188-191
[21]《中藏经》[M].北京：人民卫生出版社,2007：36-37
[22]清·沈金鳌.《杂病源流犀烛》[M].北京：人民卫生出版社,1963：6
[23]清·林佩琴.《类证治裁》[M].北京：中国中医药出版社,1999：734
[24]仝润芍.血府逐瘀汤加减治疗弥漫性间质性肺炎46例[J].河南中医,1996,16(4)：233
[25]李柏颖.清热解毒澄其源一宋康教授治疗特发性肺纤维化经验介绍[J].浙江中西医结合杂志,2008,18(6)：359-360
[26]崔红生.毒损肺络与肺间质纤维化[J].中医杂志,2007,48(9)：858-859
[27]张天嵩,马君,韩镭.赵子贤辨治弥漫性肺间质纤维化经验[J].浙江中医杂志,1998,3：102-103
[28]王新华,张弘,徐志瑛.特发性肺间质纤维化的中西医结合治疗[J].贵阳中医学院学报,2000,22(4)：3-4
[29]张会川.中药治疗特发性急性肺间质纤维化1例[J].北京中医药大学学报,1998,
21：669
[30]岳会杰.辨证治疗特发性肺间质纤维化[J].河南中医,2005,25(4)：34-35
[31]武维屏,任传云.肺间质纤维化中医辨治思路.中医杂志,2005,46(2)：139-141
[32]蒋宁,武维屏.中医络病学说与肺间质纤维化关系初探[J].中国中医基础医学杂志,2003,9(5)：341-343
[33]张纾难.肺间质纤维化中医治疗概述[J].继续医学教育,2006,20(19)：19-31
[34]王海彤,武维屏.中医药治疗弥漫性肺间质纤维化信息讨论[J].中国中医药信息杂志,1996,3(7)：25-26
[35]李素云.曹世宏教授治疗肺间质纤维化的经验介绍[J].新中医,2003,35(9)：10-11
[36]樊茂蓉,苗青,魏鹏草.特发性肺间质纤维化的中医治疗思路[J].陕西中医,2010,5(1 0)：1370-1371
[37]姚景春.中医对问质性肺疾病认识浅析[J].实用中医内科杂志,2009,23(4)：36-37
[38]于国强.吕晓东主任医师治疗肺纤维化经验[J].实用中医内科杂志,2007,21(2)：20
[39]李辉,郑菲,朱理芬等.李国勤对特发性肺间质纤维化的临证辨治思路[J].中华中医药杂志,2009,24(9)：1166-1168
[40]龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点[J].浙江中医杂志,2001,5(4)：139
[41]徐志瑛.肺问质纤维化的辨证施治[J].浙江中西医结合杂志,2008,18(5)：265-267
[42]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因病机探讨[J].中华中医药杂志,2008,23(11)：984-986
[43]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因病机与辨证治疗[J].环球中医药,2008,1(1)：15-18
[44]林军,冯一中,顾振纶,等.丹参总酚酸对盐酸博莱霉素致肺纤维化小鼠的治疗作用[J].中草药,2008,39(3)：400-403
[45]王艳琴,王晓琴,张晓明,等.当归多糖对肺纤维化大鼠肺功能和肺系数的影响[J].甘肃中医,2010,23(11)：28-32
[46]包海勇,王亚丽,吴国泰,等.当归黄芪醇提物与水提物对实验性大鼠肺纤维化的干预作用[J].中国新药杂志,2010,19(12)：1064-1068
[47]周迎春,王峰,齐彦.三七总甙对盐酸博莱霉素诱导肺纤维化大鼠肺内结缔组织生长因子的影响[J].中国现代药物应用,2010,4(4)：125
[48]全燕,夏前明,李福祥,等.三七总皂苷对大鼠肺纤维化及结缔组织生长因子表达的影响[J].西南国防医药,2009,19(1)：23-26。
[49]孙晓芳,杨长福,牛建昭,等.三七总皂苷对肺纤维化小鼠肺组织胶原影响的实验研究[J].中医药学报,2010,38(5)：14-16
[50]李江,武芳,黄茂,等.川芎嗪注射液对盐酸博莱霉素致肺纤维化大鼠转化生长 因子干预作用的研究[J].时珍国医国药,2007,18(6)：1288-1289
[51]柴文戍,翟声平,武素琳,等.灯盏花素对实验性肺纤维化大鼠的干预作用[J].中国药理学通报,2008,24(1)：113-116
[52]宋康,骆仙芳,杨超,等.虎杖对肺纤维化大鼠MMP-2和TIMP-2表达影响的实验研究[J].中国中医药科技,2008,15(3)：184-185
[53]刘永琦,李金田,李娟魏,等.黄芪对肺纤维化大鼠血清细胞因子及肺超微构的影响[J].中国免疫学杂志,2008,24(11)：980-986
[54]张毅,李金田,刘永琦,等.黄芪多糖对肺纤维化大鼠血清中Thl/Th2细胞因子平衡、NO水平的影响[J].中国老年学杂志,2009,29(10)：1185-1190
[55]李勇,程慧琳,彭素岚,等.黄芪沙参煎剂对盐酸博莱霉素诱导的大鼠肺纤维化模型的干预作用[J].四川中医,2010,28(4)：16-18
[56]姚岚,盛丽,李东书,等.中药沙参对肺纤维化大鼠肺组织TGF-β1及TNF-α蛋白表达的影响[J].中医研究,2007,20(4)：20-23
[57]姚岚,盛丽,王莉,等.沙参对肺纤维化大鼠FN、LN的影响[J].中国工业医学杂志,2007,20(2)：118-119
[58]刘力,唐岚,徐德生,等.生地对大鼠肺间质成纤维细胞Ⅳ型胶原表达的作用[J].中成药,2008,30(2)：175-178
[59]徐佳波,李燕芹,刘斌,等.氧化苦参碱对肺纤维化大鼠肺内Th1/Th2平衡的影响[J].上海中医药大学学报,2010,24(2)：24-28
[60]陈诗斌.苦参碱对肺纤维化鼠肝细胞生长因子表达的影响[J].医学信息,2010,23(8)：2577-2581
[61]刘涛,谢敏,王浩凌,等.苦参碱、γ干扰素对大鼠肺纤维化干预作用[J].南京医科大学学报(自然科学版),2008,28(5)：592-596
[62]姜山,邵磊,杜晓光,等.昆布多糖对盐酸博莱霉素诱导的大鼠肺间质纤维化的影响[J].中国海洋药物杂志,2007,26(3)：53-54
[63]张正寿,蒋捍东,王丽娜.昆布提取物J201对盐酸博莱霉素诱导的大鼠肺纤维化的保护作用研究[J].中国临床药理学与治疗学,2007,12(3)：304-307
[64]殷宗宝,邓超,李英,等.甘草酸二铵对博莱霉素致肺纤维化大鼠的治疗作用[J].重庆医学,2011,40(2)：122-124
[65]黄艳,刘娟,张雅茹,等.枇杷叶三萜酸对博来霉素致大鼠肺纤维化的干预作用[J].中国药理学通报,2011,27(5)：642-646
[66]王媛媛,王庆,杨文海.红景天对肺纤维化大鼠MMP-2与TIMP-1表达关系的影响[J].重庆医科大学学报,2010,30(5)：689-691
[67]翁恒,曲中平.麦门冬汤加减治疗特发性肺间质纤维化32例临床观察[J].国医论坛,2008,23(1)：6-7
[68]藏金萍,辛洪涛,张欣,等.芪丹颗粒对博莱霉素致大鼠肺纤维化的Fasl、 Caspase-3表达的作用[J].现代诊断与治疗,2010,21(1)：5-8
[69]李瑞琴,宋建平,李伟,等.大黄蛰虫丸对肺纤维化模型形成阶段肺组织TNF-α表达的影响[J].时珍国医国药,2010,21(1)：105-106
[70]谢汝佳,韩冰,何小飞,等.丹芍化纤胶囊对肺纤维化大鼠肺组织中calpain2, N-κB及P38MAPK表达的影响[J].时珍国医国药,2011,22(2)：381-383
[71]唐志宇,李天朗,陈严,等.鳖甲煎丸对肺纤维化大鼠肺组织中TGF-β1表达的影响[J].四川中医,2011,29(1)：8-10
[72]徐艳玲,曲妮妮,马丽佳,等.中药复方咳喘康对盐酸博莱霉素A5致肺纤维化大鼠肺系数及肺组织形态学影响的实验研究[J].中华中医药学刊,2009,27(1)：74-76
[73]刘恩顺.芪术合剂对肺纤维化大鼠TGF-β1表达及肺组织形态的影响[J].辽宁中医杂志,2008,35(2)：301-302
[74]张念志,许祥稳,李国琳,等.参七虫草胶囊对肺纤维化大鼠TGF-β1mRNA表达的影响[J].中国中医急症,2010,19(1)：89-91
[75]蔡望喜.中药益气化纤汤抗大鼠肺纤维化的实验研究[J].广州医药大学学报,2009,26(3)：263-264
[76]张晓梅.肺纤方治疗特发性肺间质纤维化临床研究[J].北京中医药,2009,28(4)：254-255
[77]魏文君.益气活血化痰方配合西药治疗肺纤维化30例[J].陕西中医,2009,30(8)：950-951
[78]龚婕宁,郭海,魏凯峰,等.养肺活血方对肺纤维化大鼠细胞外信号调节激酶1／2和核因子K-B信号通路的影响[J].中国中医药信息杂志,2009,16(11)：21-22
[79]王琴,刘世青,李长生,等.化瘀理肺方对肺纤维化大鼠MMP-2和TIMP-1表达 的影响[J].山东大学学报(医学版),2009,47(2)：14-17
[80]贾育新,王凤仪.敦煌古方“紫苏煎”对肺间质纤维化模型大鼠血清、肺组织中HYP、LDH含量的影响[J].甘肃中医,2008,21(4)：53-54
[81]耿义红.养肺活血方对肺纤维化大鼠肺组织α-SMA表达的影响[J].江苏中医药,2010,42(12)：69-70
[82]杨珂.扶正化瘀方抗肺纤维化的药物配伍作用特点[J].中医杂志,2009,50(8)：732-733
[83]张桂才,周贤梅,仇中叶.虎芪活血煎对肺纤维化大鼠肺组织HYP含量及TGF-β1mRNA表达的影响[J].吉林中医药,2007,27(11)：49-51.
[84]段斐.复方鳖甲软肝方防治肺纤维化细胞凋亡的实验研究[J].时珍国医国药,2008,19(5)：1054-1055
[85]陈瑶,汤军,徐志瑛.祛痰散瘀软坚中药对肺纤维化大鼠肺组织病理形态学及HYP含量的影响[J].浙江中医药大学学报,2009,33(1)：33-37
[86]李戎,周蜜娟,蔡永宁,等.艾灸“肺腧”“膏育”影响BLMAS诱导肺纤维化大鼠TGF-β表达实验研究[J].中国针灸,2005：790
[87]李国勤,李辉,刘丽,等.辨治特发性肺间质纤维化经验[J].中医杂志,2009,50(2)：122-123
[88]董瑞,秦洪义,刘苹.通络益肺协定方特发性肺纤维化单元疗法临床研究[J].中医中药,2008,12(4)：16-19
[89]李辉,代嫒嫒.益气破血方治疗气虚血瘀型特发性肺间质纤维化的临床观察[J].北京中医药,2010,2(11)：839-841
[90]陈山泉.自拟方治疗特发性肺纤维化的疗效观察[J].中国疗养医学,2011,20(4)：364
[91]张晓梅,孙雪松,姜良铎,等.芪红汤对特发性肺间质纤维化患者肺功能及血氧的影响[J].中医药临床杂志,2008,20(1)：35-36
[92]杨道文,单大玲.康金散治疗肺间质纤维化临床研究[J].中国中医急症,2009,18(1)：14-15
[93]谭漪,董滟,董慧君.补虚通络法治疗特发性肺纤维化的临床研究[J].时珍国医国药,2009,20(3)：713-714
[94]钟勇.芪参益气汤联合雾化吸入布地奈德治疗特发性肺纤维化56例临床疗效观察[J].中国现代药物应用,2010,4(10)：134-135
[95]易高众,张贻秋,贺兼斌等.黄芪联合糖皮质激素治疗特发性肺纤维化的临床疗效[J].临床肺科杂志,2010,15(2)：291-292
[96]白数培.川芎辅助治疗36例慢性特发性肺纤维化的临床观察[J].中国医疗前沿,2010,5(4)：26
[79]龙涛,李莹芪.参益气滴丸治疗特发性肺纤维化32例疗效分析[J].实用中西医结合临床,2011,11(10)：112
[98]杨美菊,朱红军.参附注射液对特发性肺纤维化的治疗作用[J].医药论坛杂志,2011,32(15)：169-170
[99]尹世琦,桑玉兰.丹红注射液治疗特发性肺纤维化患者的疗效观察[J].中西医结合心脑血管病杂志,2011,9(1)：116-117
[100]贾莉.苦参碱联合强的松治疗特发性肺纤维化临床观察[J].医学信息,2011,3：1067-1068
[101]董辉.抗纤舒肺颗粒治疗特发性肺间质纤维化临床观察[J].中国中医药信息杂志,2010,17(3)：61-62
[102]王增祥,于金源,刘铭珍.克肺宁胶囊治疗特发性肺间质纤维化70例临床观察[J].中国中医急症,2009,18(2)：188-189、216
[103]翁恒,曲中平.麦门冬汤加减治疗特发性肺间质纤维化32例临床观察[J].国医论坛,2008,23(1)：6-7
[104]翁惠,马登峰.清金汤治疗特发性肺纤维化临床研究[J].甘肃中医,2011,24(1)：40-41
[105]陈萍,李素云.中西医结合治疗特发性肺纤维化38例[J].光明中医,2009,24(3)：505-506
[106]郭玉琴,杨洁.血府逐瘀汤联合压缩雾化吸入普米克令舒治疗特发性肺间质纤维化临床研究[J].中国中医急症,2009,18(10)：1590-1591
[]07]徐慧卿.针药并用治疗特发性肺纤维化疗效观察[J].上海针灸杂志,2010,9(10)：641-642
[1]王飞,陈平,曹国平,等.补阳还五汤对肺纤维化大鼠肺泡巨噬细胞肿瘤坏死因子的影响[耳中药药理与临床,2005,21(3)：5-6.
[2]曹国平,王飞,陈平.补阳还五汤对博莱霉素诱导大鼠肺纤维化过程中羟脯氨酸的含量影响[J].甘肃中医,2007,20(2)：51-52
[3]李霞.宫晓燕治疗肺纤维化理论探讨[J].辽宁中医杂志,2012,39(1)：47-48
[4]宫晓燕,王泽玉,张永和.纤克颗粒治疗特发性肺纤维化实验研究[J].长春中医学院学报,2005,25(1)：70-71
[5]张欣,辛洪涛,于静,等.益气活血法对肺纤维化动物模型细胞因子表达的影响[J].山东大学学报(医学版)2005,43(12)：1129-1131
[6]孙增涛,廉富,魏葆琳.益气活血散结法治疗特发性肺纤维化临床与实验研究[J].辽宁中医杂志,2007,34(7)：865-867
[7]张欣,辛洪涛,李怀臣,等.芪丹颗粒对大鼠肺间质纤维化转化生长因子β1mRNA和肿瘤坏死因子mRNA表达的影响[J].中国临床康复,2005,9(31)：144-146
[8]张欣,辛洪涛,李怀臣,等.芪丹颗粒治疗肺间质纤维化的实验研究[J].山东医药,2005,45(20)：6-8
[9]刘恩顺,孙增涛,廉富,等.芪术合剂干预肺纤维化大鼠TGF-β1mRNA表达的实验研究[J].天津药学,2007,19(2)：1-3
[10]燕小宁,马华,赵瑞宝.中药芪红合剂对肺间质纤维化模型大鼠肺组织中TGF-β1表达的影响的影响[J].山西中医学院学报,2007,8(2)：11-13
[11]李瑞琴,宋建平,李伟,等.大黄蛰虫丸对肺纤维化模型形成阶段肺组织TNF-α 表达的影响[J].时珍国医国药,2010,21(1)：105-106
[12]张念志,许祥稳,李国琳,等.参七虫草胶囊对肺纤维化大鼠TGF-β1mRNA表达的影响[J].中国中医急症,2010,19(1)：89-91
[13]白文,王少杰王春玲,等.中药益气活血法对博莱霉素致肺纤维化小鼠IFN-C、IL-4的影响[J].北京中医药大学学报,2007,30(6)：401-405
[14]翟华强,杨毅,姜楠.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893
[15]郭书文,王国华,杨蟠储等.益气活血化痰方对肺纤维化大鼠支气管肺泡灌洗液中层粘连蛋白、III型前胶原含量的影响[J].中国中医药信息杂志,2006,13(11)：43-44
[16]刘玉庆,李谈,刘贵颖.益气活血方对肺纤维化黏附分子表达影响的实验研究[J].天津中医药,2009,26(1)：54-56
[17]关天宇,焦阳,杨效华,等.肺痹汤对肺间质纤维化大鼠血清细胞外基质影响的实验研究[J].中国中医基础医学杂志,2007,13(1)：50-51
[18]蒋宁.保肺方对肺间质纤维化大鼠模型细胞外基质代谢影响的实验研究[D].北京中医药大学博士学位论文,2004,6
[19]张永全.补阳还五汤治疗气虚血瘀型脑梗死的临床疗效及对血流速度的影响[J].中国中医急症,2010,19(8)：1288-1289
[20]黄清苑.补阳还五汤治疗缺血性中风对神经功能的影响[J].河北医学,2011,17(7)：973-974
[21]张利军.补阳还五汤治疗脑梗死临床疗效观察[J].中医药导报,2009,15(1)：23-24
[22]白会强.补阳还五汤对稳定性心绞痛患者CRP、IL-6和IL-1的影响及其相关性研究[J].中药药理与临床,2009,25(2)：110-113
[23]刘革命.补阳还五汤对冠状动脉粥样硬化性心脏病左室舒张功能的影响[J].河北中医,2009,31(11)：1658-1659
[24]秦永山.补阳还五汤治疗糖尿病周围神经病变128例[J].甘肃中医,2010,23(4)：47
[25]王琳,李伟,杨铭,等.黄芪皂苷注射液对急性心衰犬心功能和血流动力学的影响[J].中国老年医学杂志,2009,29(15)：1913-1915
[26]朱海燕.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子表达的影响[J].辽宁中医杂志,2008,35(1)：7-9
[27]林梦感,杨义芳,许海燕.黄芪多糖MAPS-5的化学结构及其体外淋巴细胞增殖活性[J].中草药,2009,40(12)：1865
[28]Lee K Y, Jeon Y J. Macrophage activation by polysaccharide iso-Lated from Astragalus membranaceus[J]. Int Immunopharmacol,2005,5(7/8):1225
[29]L H Zhao, Z X Ma, J Zhu, et al. Characterization of polysaccha-Ride from Astragalus radix as the macrophage stimulator[J]. CellImmunol,2011,271 (2):329
[30]廖苇萍,石元刚.黄芪多糖和大豆异黄酮对糖尿病大鼠糖代谢的影响[J].第三军医大学学报,2007,29(5)：416-418
[31]黄宏思.黄芪多糖协同抗癌药物对肿瘤细胞的杀伤作用[J].中国现代临床医学,2007,6(4)：35-37
[32]牛春红,刘斌焰,邢雁霞,等.黄芪多糖对四氯化碳肝损伤保护的影响[J].中国医学工程,2012,20(3)：38-39
[33]郑兰兵,魏青,刘小玲,等.黄芪多糖体外抗CVB病毒活性[J].中国医药指南,2011,9(13)：45-46
[34]赵莲芳,郑玉淑,朴惠顺,等.黄芪多糖及人参总皂苷对衰老小鼠的抗衰老作用[J].延边大学医学学报,2006,29(4)：249-251
[35]孙梅.黄芪多糖对LPS损伤小肠上皮细胞的保护作用[J].世界华人消化杂志,2008,16(1)：15-17
[36]Liu P J, Hsieh W T, Huang S H, et al. Hematopoietic effect of water-sol-ublepoly saccharides from Angelica sinensis on mice with acute bloodless[J]. Experiment al Hematology,2010,38:437
[37]柳永青.当归的化学成分与生物活性[J].沈阳航空航天医药,2009,20(11)：127
[38]杜小丽,王改琴,吴宏,等.当归多糖对小鼠造血细胞表面粘附分子表达的影响[J].重庆医科大学学报,2008,33(3)：274
[39]杨铁虹,贾敏,梅其炳.当归多糖对小鼠免疫功能的调节作用[J].中成药,2005,27(5)：563-565
[40]胡慧娟,杭秉茜,王明书.当归的抗炎作用[J].中国中药杂志,2009,16(11)：684-687
[41]聂蓉.当归多糖预防小鼠急性四氯化碳性肝损伤的研究[J].武汉工业学院学报,2008,27(4)：23
[42]黄海霞,莫晓燕,杜晓阳.赤芍总苷对培养乳鼠心肌细胞损伤后细胞凋亡的影响[J].时珍国药国医,2005,16(10)：963-965
[43]朱慧民,牟华明.赤芍对球囊损伤术后血管内膜单核细胞趋化蛋白-1基因表达的影响[J].中国中西医结合急救杂志,2008,15(3)：138-141
[44]何延龙,周端,董六一.赤芍总苷对大鼠局灶性脑缺血再灌注损伤的保护效果[J].中国临床康复,2006,10(39)：59-61
[45]许惠玉,陈志伟,牛建昭,等.赤芍总苷诱导K562细胞凋亡及对线粒体膜电位和Ca2+的影响[J].中国组织工程研究与临床康复,2008,12(16)：3123-3126
[46]Sheng H U, Chen S M, Li X K, et al. Antitumor effects of Chi-Shen extract from Salvia miltiorrhiza and Paeoniae Radix on human hepatocellular carcinoma cells[J]. Acta Pharma col Sin,2007,28(8):1215-1223
[47]Lv G, Zheng J, Zhou H, et al. The screening and isolation of an effective anti-endotoxin monomer from radix paeoniae rubra using affinity biosensor technology[J]. Int J Im munopharm ac ol,2005,5:1007-1017
[48]Lee B, Shin Y W, Bae E A,et al. Antiallergic effect of the Root of Paeonia lac tiflora and its constituents pae on iflor in And paeonol[J]. Arch Pharm Res,2008,31(4):445-450
[49]詹秀琴,戴启刚,樊文玲.地龙生物活性部位经膜分级分离后降压作用的比较研究[J]生物学通报,2010,45(9)：24-26
[50]杨明.高速逆流色谱分离地龙中抗血栓活性成分的研究[J].中国医药导刊,2010,12(7)：32-35
[51]刘英姿.地龙注射液免疫活性的体外研究[J].安徽农业科学,2009,37(35)：17514-17517
[52]杨明,陈学东,彭辑地龙蛋白组分对鼻咽癌裸鼠移植瘤微血管密度的影响[J].湖南中医药大学学报,2008,28(4)：46-47’
[53]王莉,刘毅,王芬,等.地龙对哮喘模型小鼠肺组织α-SMA及纤维蛋白的抑制作用[J].中医病理生理杂志,2009,25(10)：1964-1968
[54]陆亚琴,刘顺英,陈洪,等.地龙2号抑制大鼠肝纤维化的研究[J].胃肠病学及 肝病学杂志,2004,13(3)：225-227
[55]周苏宁.川芎嗪心血管药理的研究[J].中药药理与临床,2001,7(3)：311
[56]梁日欣,廖福龙,韩东.川芎嗪预处理对麻醉家兔心肌缺血再灌注损伤的保护作用[J].中药药理与临床,2000,16(2)：11
[57]黄美杏,陈学远,龙学明,等.川芎嗪对慢性肺心病急性加重期患者肺功能与血管活性物质的影响[J].实用医学杂志,2005,3(19)：602
[58]朱全刚,胡晋红,黄瑾,等.阿魏酸及其衍生物的药理作用[J].中药材,2001(7)：1992-2000
[59]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].中国中西医结合杂志,2005,25(4)：345
[60]耿涛,谢梅林,彭少平.桃仁提取物抗大鼠心肌缺血作用的研究[J].苏州大学学报,2005,25(2)：238-240
[61]洪长福,娄金萍,周华仕,等.桃仁提取物对大鼠实验性矽肺纤维化的影响[J].劳动医学,2000,17(4)：218
[62]张晓平,陈建明,强世平,等.山桃仁水煎提取物对肝纤维化小鼠血清I、III型前胶原的降解作用[J].福建中医药,2002,33(4)：361
[63]邱蓉丽,李磷.桃仁正品来源品种脂肪油和氨基酸分析与比较[J].中国药师,2008,11(12)：1426-1428
[64]郑为超,陈铎葆,张雷,等.红花黄色素对缺血心肌的影响及机制研究[J].中国药理学通报,2005,21(8)：978-980
[65]臧宝霞,金鸣,司南,等.羟基红花黄色素A对血小板活化因子的拮抗作用[J].药学学报,2002,37(9)：696
[66]金鸣,高子淳,王继峰.羟基红花黄色素A抑制PAF诱发的家兔血小板活化的研究[J].北京中医药大学学报,2004,27(5)：32
[67]田京伟,傅风华,蒋王林,等.羟基红花黄色素A对脑缺血所致大鼠脑线粒体损伤的保护作用[J].药学学报,2004,39(10)：774
[68]梁辉,范金英,李爱华,等.羟基红花黄色素A对大鼠局灶性脑缺血再灌注NMDAR1蛋白表达的影响[J].中华老年心脑血管病杂志,2004,6(3)：194
[69]费娅丽,黄小民.红花注射液对大鼠内毒素性肝损伤保护机制的研究[J].中国中 医急症,2009,18(6)：948
[70]陈志强,王万强,叶秀云,等.红花注射液对脑缺血/再灌注损伤家兔血清白细胞介素IL-8的影响[J].中国急救医学,2005,25(2)：118
[71]金鸣,李金荣,吴伟.羟基红花黄色素A抗氧化作用的研究[J].中草药,2004,35(6)：665
[2]陆再英,钟南山.内科学(第7版)[M].北京：人民卫生出版社,2008；10：101
[3]张丽.肺纤维化的治疗现状及展望[J].肿瘤预防与治疗,2009,22(1)：100-103
[4]Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis:impact of oxygen and colchicines, prednisone, or no therapy on survival. AmJ Respir Crit Care Med, 2000,161:1172-1178
[5]K A sk, G E M. Martin, M. Kolb, et al. Targeting genes for treatment in idiopathic pu-lmonary fibrosis [J]. Proc Am Tho rac Soc,2006,3:389-393
[6]Tashkin D P, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cycloph-osphamide on out comes at 2 years in scleroderma a lung disease [J]. Am J Respir Crit Care Med,2007,176:1026-1034
[7]Meurer S K, Tihaa L, Lahme B, et al. Identification of endoglin in rat hepatic stellate cells:new insights into transforming growth factor beta receptor signaling. J Biol Chem, 2005,280(4):3078-3087
[8]Isaka Y, Tsnjie M, Asado Y, et al. Transforming growth factor-beta 1 antisense oligo-deoxy-nucleotides block interstitial fbrosis in un ilateral ureteral obstruction. Kidney Int, 2000,58(5):1885-1892
[9]Ten Dijke P,I-I511 CS. New insights into TGF-beta/Smad signaling. Trends Biochem Sci,2004,29(5):265-273
[10]Park SH. Fine tuning and cross-talking of TGF-beta singal by inhibitory smads. J Biochem Mol Biol,2005,38(1):9-16
[11]Hasegawa T, Nakao A, Sumiyoshi K, et al. SB2431542 Inhibits T-GF-β-induced contraction of collagen gel by normal and keloid fibroblasts.J Dermatol Sci,2005,39(1): 33-38
[12]Huang M, Sharma S, Zhu L X, et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis [J]. Clin Invest,2002,109(7):931-937
[13]Kamaraju A K,Roberts A B. Role ofRho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carciuoma cells in vivo. J Biol Chem,2005,280(2):1024-1036
[14]Bonniaud P, Margetts PJ, Kolb M, et al.Transient transgene expression of CTGF in the lung induces mode-rate and reversible fibrosis. Eur Respir J,2002,20(38):378-389
[15]Flanders KC. Smad3 as a mediator of the fibrotic response. International Journal of Experimental Pathology,2004,85(2):47-64
[16]Nakao A, Fnjii M, Matsumura R'et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lun g fibrosis in mice [J]. Clha Invest,1999,104(1): 5-11
[17]GaoJ, LiuPQ. Connectivet issue growth factor and its role in cardio vascular disease [J]. MedRecap,2006,12(20):1219-1221
[18]Secker G A, Shot A J, Sampson E, et al.TGF beta stimulated reepithelialisation is regulated by CTGF and Ras/MEK/ERK signaling[J].Exp Cell Res,2008,314(1):131-42
[19]黄长海,杨敏,李惊自,等.结缔组织生长因子通过活化ERK1/2信号通路促成纤维细胞生成[J].中华医学杂志,2005,85：1322-1327
[20]Kim C S, Kim J M, Nam S Y, et al. Low-dose of ionizing radiation enhances cell pr-oliferation via transient ERK1/2 and p38 activation in normal human lung fibroblasts. J Radiat Res,2007,48(5):407-415
[21]Riser BL, Denichilo M, ConesP, etal.Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression diabetic glomerulosclerosis[J]. Jam Soc Nephrol,2000,11(1):25-38
[22]杨雅茹,黄艳,李俊.TGF-pl介导的Smads与ERK通路在肺纤维化中的作用及相互关系[J].中国药理学通报,2010,26(5)：561-563
[23]Stroschein S L, Wang W, LuoKX.Cooperative binding of Smad proteins to two adja-cent DNA elements in the plasminogen activator in hibitor-1 promoter mediates transfor-ming growth factorβ-induced smad-dependent transcriptional activation[J].J Biol Chem, 1999,274(14):9431-41
[24]TaoY Y, Wang X L, LiuCH. Salvianolic acid-B effects on TGF-B1/ERK signaling transducfion in NIH/3T3 fibroblast[J]. J Cap Med Univ,2007,28(2):192-195
[25]俞新,杨继兵.肺纤维化中医药研究进展[J].中华现代中医学杂志,2010,6(1)：14-16
[26]杨瑶,潘强,王世岭,等.中药治疗肺纤维化的研究进展[J].中国药业,2004,13(8)：21-24
[27]黄霞,袁效涵,等.肺纤维化病因学及中医药实验研究现状[J].辽宁中医杂志,2008,35(12)：1946-1949
[28]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP-22和TIMP-1表达的影响[J]华中科技大学学报·医学版,2006,36(1)：35-56
[29]盛丽,姚岚,王丽,等.水蛭、地龙抗实验性小鼠肺纤维化作用的研究[J].中医研究,2006,09(2)：15-17
[30]葛敏,戴令娟.川芎丹参提取液对大鼠肺纤维化的影响研究[J].实用临床医药杂志,2006,10(5)：75-77
[31]柴文戍,于镜泊,李永春.当归对肺纤维化大鼠肺形态学及胶原的影响[J].中国全科医学,2004,7(8)：531-533
[32]刘玉庆,李谈,等.益气活血方对肺纤维化黏附分子表达影响的实验研究[J].天津中医药,2009,26(1)：54-56
[33]孙增涛,封继宏,等.益气活血散结法对肺纤维化的干预效果及机制研究[J].天津中医药大学学报,2008,27(3)：209-212
[34]翟华强,杨毅,等.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893
[35]Noble PW, Homer RJ. Idiopathic pulmonary fibrosis:new insights into pathogenesis. Clin Chest Med.2004,25(4):749-58, vii. Review
[36]Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta 1:potential role in idiopathic pulmonary fibrosis. Am J Pathol,2005,166(5):1321
[37]Bhatt N, Baran CP, Allen J, Magro C, Marsh CB.Promising pharmacologic innovations in treating pulmonary fibrosis. Current Opinion in Pharmacology,2006,6: 284-92
[38]Szapiel S V, Elson Na, Fulmer J D, et al. Bleomycin induced interstitial pulmonary disease in the nude, athymic mouse [J]. Am Rev Respir Dis,1979,120:893-9
[39]Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol,2005,32:342-9
[40]Barbarin V, Xing Z, Delos M, Lison D, Huaux F. Pulmonary over expression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol,2005,288 (5):L841-L848
[41]刘干,李俊,高建,等.肺纤维化模型研究进展[J].安徽医药,2012,14(10)：1117-20
[42]左竹林,段生会.百草枯中毒和百草枯肺[J].中国临床医生,2000,28(8)：22
[43]Card JW, Racz WJ, Brien JF,et al. Differential effects of pirfenidone on acute pulmo-nary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity[J]. Toxicological Sciences,2003,75:169-180
[44]王世鑫.二氧化硅粉尘致肺纤维化机制及早期生物标记物研究[D].重庆大学博士论文,2004,10
[45]胡晓玲.免疫复合物致大鼠肺间质纤维化作用的研究[J].青岛大学医学院学报,2004,40(2)：112-116
[46]孔琪,秦川.SARS市纤维化发病机制的比较医学研究[J].中国比较医学杂志,2005,15(6)：335-338
[47]韩光,周云峰,彭敏,等.小鼠放射性肺损伤模型的建立与鉴定[J].中华放射医学与防护杂志,2006,26(5)：442-4
[48]GEISER T. Idiopathic pulmonary fibrosism disorder of alveolar wound repair[J]. Swiss Med Wkly,2003,133(29-30):405-411
[49]Felix C, Jack G, Geofrey J. Pulmonary fibrosis searching for model answers[J]. Am J Respir Cell Mol Biol,2005,33:9-13
[50]SniderGL, CelliBR, GoldsteinRH, et al. Chronic interstitial pulmonary fibrosis prod-uced in hamsters by endotrachel bleomyein. Am Rev Res Pir Dis 1978,117:289-297
[51]Manoury B, NenanS, Guenonl, et al. Maero Phage metalloelastase(MMP-12) defic-iency does not alter bleomycin-induced Pulmonary fibrosis in mice. J Inflamm(Lond), 2006,3:2
[52]Gharaee M, Ullenbruch M, Phan SH. Animal models of pulmonary Fibrosis J. Meth-ods Mol Med,2005,117:251-259
[53]蔡颖.肺纤维化的药物治疗进展[J].世界临床药物,2008,29(1)：17-19
[54]Selman M, Thannickal V, Pardo A, et al. Idiopathic pulmonary fibrosis:pathofenes-is and therapeutic approaches. Drugs,2004,64:405-430
[55]崔冰,胡卓伟.抗肺纤维化药物治疗研究进展[J].生理科学进展,2008,39(3)：233-238
[56]魏茂提,王世鑫,张国辉,等.染矽尘大鼠肺脏系数和肺胶原含量的变化[J].工业卫生与职业病,2001,27(6)：351-353
[57]Xiuxia Zhou, Haizhen Hu, Mai-Lan N. H, et al. Mechanisms of tissue inhibitor of metalloproteinase-1 augmentation by IL-13 on TGF- beta 1- stimulated primary human fibroblasts. J Allergy Clin Immunol,2007,119(6):1388-97
[58]孙旭明,何振华,陈林.肺间质纤维基质重建与肺纤维化的研究进展[J].中国实用医药,2011,6(24)：242-244
[59]郝小惠,张丽,王献华.胶原与肺间质纤维化的研究进展[J].华北煤炭医学院学报,2005,7(1)：43-45
[60]彭丽芬.支气管肺泡灌洗液对特发性肺间质纤维化的诊断价值[J].中国医学研究与临床,2003,1：75
[61]王佑娟,曾莉,吴琴琴,等.特发性肺纤维化患者血中细胞外基质成分的变化及与肺功能指标的关系[J].实用医学杂志,2008,24(21)：3699-70
[62]Van HoozenB E, Grimmer K L, Marelieh G P et al. Early Phase collagen synthesis in lungs of rats exposed to bleomyein[J]. Toxieology,2000,147(1):1-13
[63]周明先.肺结核患者血清纤维化指标测定及意义[J].放射免疫学杂志,2009,19(1)：25-26
[64]王希明,陈学奎.透明质酸与呼吸系统疾病[J].临床肺科杂志,2008,13(9)：1185
[65]Ueki N, Taguehi T, Takahshi M, et al. Inhibition of hyaluronan synthesis by veasnari-none in cultured human myofibroblasts[J]. Biochim Biophys Acta,2000,1495(2):160
[66]牛建昭,责长恩.器官纤维化基础及中医药防治[M].北京：人民卫生出版社,2008：102
[67]杨汀,王辰,庞宝森,等.透明质酸对大鼠肺泡巨噬细胞和肺成纤维细胞分泌蛋白酶的影响[J].中国病理生理杂志,2009,25(3)：541-546
[68]张青竹,郭丽萍.肺结核继发性纤维化指标检测的临床研究[J].实用心脑肺血管病杂志,2011,19(2)：191-193
[69]LaPPi-Blaneo E, Kaarteenaho-Wiik R, Salo S, et al. Laminin-5 gamma2 chain in cry-ptogenic organizing pneumonia and idiopathic pulmonary fibrosisl[J]. Am J Res Pir Crit Care, Med,2004,169(1):27-33
[70]Christopher J A, Juan X C, Sonja H, et al. Mycobacterium tuberculosis produces pili during human infection [J]. PNAS,2007,104(12):5145-50
[71]徐峥嵘.细胞因子及其特异性抑制剂与肺纤维化的治疗[J].中国公共卫生,21(6)：750-753
[72]胡迎春,贺性鹏.层粘连蛋白与肺纤维化病变关系的研究进展[J].医学综述,2010,16(4)：484-486
[73]费雁.芪丹化纤方对大鼠肺纤维化的干预作用及机制研究[D].湖北中医学院博士论文,2009,5：41-42
[74]Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med.2002,166(6):839-42
[75]Bhatt N, Baran CP, Allen J, Magro C, Marsh CB. Promising pharmacologic innovati-ons in treating pulmonary fibrosis. Current Opinion in Pharmacology,2006,6:284-292
[76]Torsten R, Dunkern, Daniel F, Giovanni A. et al. Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activat-ors of soluble guanylyl cyclase.European Journal of Pharmacology,2007,572:12-22
[77]Yun Zhao, Dawn A. Geverd Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis:a negative feedback loop of TGF-β signaling. Biochemical and Biop-hysical Research Communications,2002,294:319-323
[78]Evans R A, Tian Y C, Steadman R, et al. TGF-betal mediated fibroblast-myofibrobl-ast terminal differentiation-the role of Smad proteins. Exp Cell Res.2003,282(2):90-100
[79]Antoniou K M, Pataka A, Bouros D, et al. Pathogenetic pathways and novel pharma- cotherapeutic targets in idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Ther-apeutics.2007,20(5):453-61
[80]Yamamura Y, Hua X, Bergelson S, et al. Critical role of Smads and AP-1 complex in transforming growth factor-beta dependent apoptosis. J BolChem,2000,275(46): 36295-36302
[81]Chen W, Fu XB, Sheng ZY. Review of current progress in the structure and function of Smad protein. Chinese Medical Journal,2002,115(3):446-450
[82]牛建昭,责长恩.器官纤维化基础及中医药防治[M].北京：人民卫生出版社,2008：102
[83]黄顺玲.肝脏靶向性导入TGF-β1isiRNA对急性肝损伤大鼠TGF-p/Smad信号传导通路的影响.中南大学博士论文,2007,5：23
[84]Van Hoozen B E, Grimmer K L, Marelieh G P, et al. Early Phase collagen synthesis in lungs of rats exposed to bleomycin[J]. Toxicology,2000,147(1):1-13
[85]Reiser K M, Hesterberg T W, Hasehek W M, et al. Experimental silicosis:1. Acute ef-fects of intratracheally instilled quartz on collagen metabolism and morphologic characte-ristics of rat lungs. Am J Pathol,1982,107:176-185
[86]马跃文.TGF-β1与其TβRⅠ、TβRⅡ影响博莱霉素致大鼠纤维化肺内胶原Ⅰ、Ⅲ Ⅳ、Ⅴ型沉积的研究[D].中国医科大学博士论文,1997,3：45-46
[87]Cutroneo K R, White S L, Phan S H, et al. Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression [J]. J Cell physiol, 2007,211(3):585-589
[88]Lee C G, Cho S J, Kang M J, et al. Early growth response gene 1 mediated apoptosis is essential for transforming growth factor beta 1-induced pulmonary fibrosis. Exp Med, 2004,200:377-389
[89]Gauldie J, Kolb M, Ask K. Smad3 signaling involved in pulmonary fibrosis and Emphysema. The Proeeedings of the American Thoracic Society,2006,3:696-702
[90]Ask K, Boxuliaud P, Maass K, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoforml but not TGF-beta3. Int. J Biochem Cell BiOl,2008,40:484-495
[91]徐国萍,徐达.TGF-p,诱导的肺泡Ⅱ型上皮细胞向间质细胞转变[J].复旦学报,2007,34(2)：223-227
[92]Alberti A, Sarchielli P, Gallinella E, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome:a Preliminary study[J]. J Sleep Res,2003,12(4):305-311
[93]余维涛,崔社怀,杨雪梅.特异性stealth siRNA抑制小鼠肺成纤维细胞TGF-β1表达的实验研究[J].第三军医大学学报,2007,29(21)：8302
[94]Scotton C J, Chambers R C. Molecular targets in pulmonary fibrosis:the myofibrob-last in focus [J]. Chest,2007,132:1311-1321
[95]Kim K K, Kugler M C, Wolters P J, et al. Alveolar epithelial cell mesenchymal tran-sition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci USA,2006,103:13180-13185
[96]Amanda Goodwin, Gisli Jenkins. Role of integrin-mediated TGF-β activation in the pathogenesis of pulmonary fibrosis[J]. Biochemical Society Transactions,2009,37:849-854
[97]芮炜玮,转化生长因子β1及相关细胞因子在肺纤维化发生中的作用[J].同济大学学报(医学版),2010,31(3)：133-136
[98]Ask K, Boxuliaud P, Maass K, e tal. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Bioehem Cell Bi01.2008,40:484-495
[99]Kenneth R C, Shery L W, Sem H P, et al. Therapies for bleomycin indueed lung fibro-sis through regulation of TGF-β1 induced collagen gene expression. J Cell. Physiol,2007, 211(8):585-589
[100]Massague J. TGF-beta in Cancer. Cell,2008,134(2):215-230
[101]Kohei M, Hiroyuki S, Takeshi M, et al. Imamura Regulation of TGF-βsignaling and its roles in progression of tumor. Cancer,2003,94(3):230-234
[102]Yamamura Y, Hua X, Bergelson S, et al. Critical role of Smads and AP-1 complex in transforming growth factor-beta dependent apoptosis. J Bol Chem,2000,275(46):36295-36302
[103]Chen W, Fu XB,Sheng ZY. Review of current progress in the structure and function of Smad protein. Chinese Medical Journal,2002,115(3):446-450
[104]陈卫花,程慧敏,孔庆兖,等TGF-β信号通路及细胞黏附分子在非小细胞肺癌 的研究[J].徐州医学院学报,2007,27(8)：522-528
[105]Schmierer B, Hill CS. TGF-beta-Smad signal transduction molecular specificity and functional flexibility. Nat Rev Mol Cell Biol,2007,8(12):970-982
[106]Konrad L, Scheiber JA, Volck-Badouin E, et al. Alternative splicing of TGF-betas and their high-affinity receptors T beta R I, T beta R II and Tbeta R III (betaglycan) reveal new Variants in human prostatic cells. RMC Genomics,2007,11(8):318-330
[107]Razzaque M S, Taguchi T. Pulmonary fibrosis:cellular and molecular events. Pathol Int.2003,53(3):133-45
[108]Gail E, Martin M, Kjetil A S K, et al. The transforming growth factor-beta (TGF-β) family and pulmoary fibrosis.Drug Discover Today:Dis Meeh,2006,3:99-103
[109]Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and resistent to TGF-beta-mediated pulmonary fibrosis. J Inmunol.2004,173:2099-2108
[110]Hiroyuki Higashiyama. Receptor-activated Smad localization in Bleomycin-Induced Pulmonary fibrosis. J Clin Pathol Mar 2007,60:283-289
[111]Amle V G, Frederipue L B.Imbalance of Receptor-regulated and Inhibitory Smads in lung fibroblasts from bleomyein exposed rats. Am J Res Pir Cell Mol Biol,2007,36: 206-212
[112]Bonniaud P, MargettsP J, Ask K. TGF-p and Smad3 signaling link inflammation to chronic fibrogenesis. Journal of Immunology,2005,175:5390-5395
[113]Gauldie J, Bonniaud P, Sime P, etal.TGF-beta, Smad3 and the process of Progressive fibrosis. Biochem Soc Trans,2007,35(4):661-664
[114]Flanders K C.Smad3 as a mediator of the fibrotic response. Int J Exp Pathol,2004, 85(2):47-64
[115]Higashiyama H, Yoshimoto D, OkamotoY, et al.Receptor-activated Smad localisa-tion in bleomycin-indueed pulmonary fibrosis. J Clin Pathol,2007,60(3):283-289
[116]Fukasawa H, Yamamoto T, Togawa A. Down-regulation of Smad7 expression by ubiquitindependent degradation contributes to renal fibrosis in obstruetive nephropathy in mice. PNAS.2004,101(23):8687-8692
[117]Galvin K M, Donovan M J, Froneh C A, et al. A role for Smad7 in development and homeostasis of the cardiovascular system. Nat Genet,2000,24(2):171-174
[118]Suzuki C, Murakami G Fukuehi M, et al. Smurfl regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem,2002,277(42):39919 39925
[119]Zhao J, Shi W, Chen H, et al. Smad7 and Smad6 differentially modulate transformi-ing growth factor β-induced inhibition of embryonic lung morphogenesis. J Biol Chem, 2000,275:23992-23997
[120]Nakao A, Okumura K, Ogawa H. Smad7:a new key player in TGF-beta associated disease. Trends Mol Med,2002,8(8):361-363
[121]Huang M, Sharma S, Zhu L X, et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest,2002,109(7):931-937
[122]Venkatesan N, pini L, Ludwig M S. Changes in Smad expression and subcellular localization in bleomycin-indueed pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2004,287:1342-134
[123]高建.当归补血总苷的研制及对实验性肺纤维化的干预作用和分子机制研究[D].2009,6：84
[124]徐芳,徐启勇,叶燕青.ERK信号通路在肺纤维化大鼠中的研究[J].武汉大学学报(医学版),2005(03)：322-325
[125]Ben-David H, Aruna B V, Seger R, et al. A 50-kDaERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses[J]. Proc Natl Acad Sci USA,2006,103(48):18232-18237
[126]杨雅茹,黄艳,李俊.TGF-β1介导的Smads与ERK通路在肺纤维化中的作用及相互关系[J].中国药理学通报,2010,21(5)：561-563
[127]Ranzato E, Patrone M, Pedrazzi M, et al. HMGbl promotes scratch wound closure of HaCaT keratinocytes via ERK1/2 activation[J]. Mol Cell Biochem,2009,332(1-2): 199-205
[128]Ranzato E, Patrone M, Pedrazzi M, et al. Hmgbl promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation[J]. Cell Biochem Biophys, 2010,57(1):9-17
[129]Davis B H, Chen A, Beno D A. Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression[J]. J Biol Chem,1996,271:11039-11042
[130]Mucsi I, Skorecki K L, Goldberg H J. Extracellular signal-regulated kinase and the small GTP-binding protein, rac, contribute to the effects of transforming growth factorpi on gene expression[J].Bid Chem,1996,271:16567-16572
[131]Huang C H, Yang M, Li J Z, et al. Connective tissue growth factor contribute to the growth of myofibroblast by activating ERKI/2 signaling pathway [J]. Chin Med,2005,85: 1322-1327
[132]赵辉平,王胜春,胡咏斌.五灵胶囊对肝纤维化大鼠肝组织TGF-β1/Smad及Ras/ERK信号通路蛋白的影响[J].胃肠病学和肝病学杂志,2009,18(5)：392-396
[133]Hayashide T, Decaestecker M, Schnaper H W. Crosstalk between ERK/MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses ill human mesan-gial ceils[J]. FASEB J,2003,17(11):1576-1578
[134]冯莉,王献华.转化生长因子-p1介导的ERK/MAPK信号通路与肺纤维化[J].中国煤炭工业医学杂志,2008,11(10)：1621-1623
[135]Fubini B, Hubbard A. Reactive oxygen species(ROS)and reactive nitrogen species (RNS)generation by silica in inflammation and fibrosis[J]. Free Radic Biol Med,2003, 34(12):1507-1516
[136]Robledo R F, Buder-Hofmann S A, Cummins A B, at al. Increased phosphorylated extracellular signal regulated kinase immune reactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice[J]. Am J Pathol, 2000,156(4):1307-1316
[137]Kimcs C S, Kim J M, Nam SY, et al. Low-dose of ionizing radiation enhances cell proliferation via transient ERKI/2 and p38 activation in normal human lung fibroblasts. J Radiat Res,2007,48(5):407-415
[1]姚楚芳.中医药防治肺间质纤维化[J].中西医结合学报,2003,1(3)：234-238
[2]陈惠.中西医结合治疗肺间质纤维化的临床进展[J].黑龙江中药,2004,2：63-64
[3]陈瑞,王鹏.浅谈肺痹与特发性肺纤维化的关系[J].中国中医药信息杂志,2005,12(6)：90-91
[4]王永炎,晁恩祥主编.今日中医内科[M].北京：人民卫生出版社,2000：309
[5]黄帝内经素问[M].北京：人民卫生出版社,1996：538
[6]张仲景(汉).金匮要略[M].北京：人民卫生出版社,2005：25
[7]巢元方(隋).诸病源候论[M].北京：人民卫生出版社,1956：11
[8]韩学杰主编.孙一奎医学全书[M].北京：中国中医药出版社,1999：174
[9]王肯堂(明).证治准绳[M].北京：人民卫生出版社,1991：145
[10]田代华整理.黄帝内经素问.北京：人民卫生出版社,2005：124
[11]田代华,刘更生整理.灵枢经[M].北京：人民卫生出版社,2005：14
[12]秦景明(明).症因脉治[M].北京：中国中医药出版社,1998：239
[13]陈士铎(清).辨证录[M].北京：中国中医药出版社,1995：55
[14]叶天士(清),临证指南医案[M].上海：上海科技出版社,2000：294
[15]谢观.中华医学大辞典[M].沈阳：辽宁科技出版社,1994：872
[16]孙思邈(唐).千金要方[M].北京：人民卫生出版社,1956：315
[17]喻嘉言(清).医门法律(喻嘉言医学全书)[M].北京：中国中医药出版社,1999：361
[18]巢元方(隋).诸病源候论[M].北京：人民卫生出版社,1956：82
[19]郑洪新主编.周学海医学全书[M].北京：中国中医药出版社,1999：276
[20]清·叶天士.《临证指南医案》[M].北京：人民卫生出版社,2008：188-191
[21]《中藏经》[M].北京：人民卫生出版社,2007：36-37
[22]清·沈金鳌.《杂病源流犀烛》[M].北京：人民卫生出版社,1963：6
[23]清·林佩琴.《类证治裁》[M].北京：中国中医药出版社,1999：734
[24]仝润芍.血府逐瘀汤加减治疗弥漫性间质性肺炎46例[J].河南中医,1996,16(4)：233
[25]李柏颖.清热解毒澄其源一宋康教授治疗特发性肺纤维化经验介绍[J].浙江中西医结合杂志,2008,18(6)：359-360
[26]崔红生.毒损肺络与肺间质纤维化[J].中医杂志,2007,48(9)：858-859
[27]张天嵩,马君,韩镭.赵子贤辨治弥漫性肺间质纤维化经验[J].浙江中医杂志,1998,3：102-103
[28]王新华,张弘,徐志瑛.特发性肺间质纤维化的中西医结合治疗[J].贵阳中医学院学报,2000,22(4)：3-4
[29]张会川.中药治疗特发性急性肺间质纤维化1例[J].北京中医药大学学报,1998,
21：669
[30]岳会杰.辨证治疗特发性肺间质纤维化[J].河南中医,2005,25(4)：34-35
[31]武维屏,任传云.肺间质纤维化中医辨治思路.中医杂志,2005,46(2)：139-141
[32]蒋宁,武维屏.中医络病学说与肺间质纤维化关系初探[J].中国中医基础医学杂志,2003,9(5)：341-343
[33]张纾难.肺间质纤维化中医治疗概述[J].继续医学教育,2006,20(19)：19-31
[34]王海彤,武维屏.中医药治疗弥漫性肺间质纤维化信息讨论[J].中国中医药信息杂志,1996,3(7)：25-26
[35]李素云.曹世宏教授治疗肺间质纤维化的经验介绍[J].新中医,2003,35(9)：10-11
[36]樊茂蓉,苗青,魏鹏草.特发性肺间质纤维化的中医治疗思路[J].陕西中医,2010,5(1 0)：1370-1371
[37]姚景春.中医对问质性肺疾病认识浅析[J].实用中医内科杂志,2009,23(4)：36-37
[38]于国强.吕晓东主任医师治疗肺纤维化经验[J].实用中医内科杂志,2007,21(2)：20
[39]李辉,郑菲,朱理芬等.李国勤对特发性肺间质纤维化的临证辨治思路[J].中华中医药杂志,2009,24(9)：1166-1168
[40]龚婕宁,王灿晖.论肺间质纤维化的中医病理学特点[J].浙江中医杂志,2001,5(4)：139
[41]徐志瑛.肺问质纤维化的辨证施治[J].浙江中西医结合杂志,2008,18(5)：265-267
[42]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因病机探讨[J].中华中医药杂志,2008,23(11)：984-986
[43]姜良铎,张晓梅,肖培新.特发性肺间质纤维化的病因病机与辨证治疗[J].环球中医药,2008,1(1)：15-18
[44]林军,冯一中,顾振纶,等.丹参总酚酸对盐酸博莱霉素致肺纤维化小鼠的治疗作用[J].中草药,2008,39(3)：400-403
[45]王艳琴,王晓琴,张晓明,等.当归多糖对肺纤维化大鼠肺功能和肺系数的影响[J].甘肃中医,2010,23(11)：28-32
[46]包海勇,王亚丽,吴国泰,等.当归黄芪醇提物与水提物对实验性大鼠肺纤维化的干预作用[J].中国新药杂志,2010,19(12)：1064-1068
[47]周迎春,王峰,齐彦.三七总甙对盐酸博莱霉素诱导肺纤维化大鼠肺内结缔组织生长因子的影响[J].中国现代药物应用,2010,4(4)：125
[48]全燕,夏前明,李福祥,等.三七总皂苷对大鼠肺纤维化及结缔组织生长因子表达的影响[J].西南国防医药,2009,19(1)：23-26。
[49]孙晓芳,杨长福,牛建昭,等.三七总皂苷对肺纤维化小鼠肺组织胶原影响的实验研究[J].中医药学报,2010,38(5)：14-16
[50]李江,武芳,黄茂,等.川芎嗪注射液对盐酸博莱霉素致肺纤维化大鼠转化生长 因子干预作用的研究[J].时珍国医国药,2007,18(6)：1288-1289
[51]柴文戍,翟声平,武素琳,等.灯盏花素对实验性肺纤维化大鼠的干预作用[J].中国药理学通报,2008,24(1)：113-116
[52]宋康,骆仙芳,杨超,等.虎杖对肺纤维化大鼠MMP-2和TIMP-2表达影响的实验研究[J].中国中医药科技,2008,15(3)：184-185
[53]刘永琦,李金田,李娟魏,等.黄芪对肺纤维化大鼠血清细胞因子及肺超微构的影响[J].中国免疫学杂志,2008,24(11)：980-986
[54]张毅,李金田,刘永琦,等.黄芪多糖对肺纤维化大鼠血清中Thl/Th2细胞因子平衡、NO水平的影响[J].中国老年学杂志,2009,29(10)：1185-1190
[55]李勇,程慧琳,彭素岚,等.黄芪沙参煎剂对盐酸博莱霉素诱导的大鼠肺纤维化模型的干预作用[J].四川中医,2010,28(4)：16-18
[56]姚岚,盛丽,李东书,等.中药沙参对肺纤维化大鼠肺组织TGF-β1及TNF-α蛋白表达的影响[J].中医研究,2007,20(4)：20-23
[57]姚岚,盛丽,王莉,等.沙参对肺纤维化大鼠FN、LN的影响[J].中国工业医学杂志,2007,20(2)：118-119
[58]刘力,唐岚,徐德生,等.生地对大鼠肺间质成纤维细胞Ⅳ型胶原表达的作用[J].中成药,2008,30(2)：175-178
[59]徐佳波,李燕芹,刘斌,等.氧化苦参碱对肺纤维化大鼠肺内Th1/Th2平衡的影响[J].上海中医药大学学报,2010,24(2)：24-28
[60]陈诗斌.苦参碱对肺纤维化鼠肝细胞生长因子表达的影响[J].医学信息,2010,23(8)：2577-2581
[61]刘涛,谢敏,王浩凌,等.苦参碱、γ干扰素对大鼠肺纤维化干预作用[J].南京医科大学学报(自然科学版),2008,28(5)：592-596
[62]姜山,邵磊,杜晓光,等.昆布多糖对盐酸博莱霉素诱导的大鼠肺间质纤维化的影响[J].中国海洋药物杂志,2007,26(3)：53-54
[63]张正寿,蒋捍东,王丽娜.昆布提取物J201对盐酸博莱霉素诱导的大鼠肺纤维化的保护作用研究[J].中国临床药理学与治疗学,2007,12(3)：304-307
[64]殷宗宝,邓超,李英,等.甘草酸二铵对博莱霉素致肺纤维化大鼠的治疗作用[J].重庆医学,2011,40(2)：122-124
[65]黄艳,刘娟,张雅茹,等.枇杷叶三萜酸对博来霉素致大鼠肺纤维化的干预作用[J].中国药理学通报,2011,27(5)：642-646
[66]王媛媛,王庆,杨文海.红景天对肺纤维化大鼠MMP-2与TIMP-1表达关系的影响[J].重庆医科大学学报,2010,30(5)：689-691
[67]翁恒,曲中平.麦门冬汤加减治疗特发性肺间质纤维化32例临床观察[J].国医论坛,2008,23(1)：6-7
[68]藏金萍,辛洪涛,张欣,等.芪丹颗粒对博莱霉素致大鼠肺纤维化的Fasl、 Caspase-3表达的作用[J].现代诊断与治疗,2010,21(1)：5-8
[69]李瑞琴,宋建平,李伟,等.大黄蛰虫丸对肺纤维化模型形成阶段肺组织TNF-α表达的影响[J].时珍国医国药,2010,21(1)：105-106
[70]谢汝佳,韩冰,何小飞,等.丹芍化纤胶囊对肺纤维化大鼠肺组织中calpain2, N-κB及P38MAPK表达的影响[J].时珍国医国药,2011,22(2)：381-383
[71]唐志宇,李天朗,陈严,等.鳖甲煎丸对肺纤维化大鼠肺组织中TGF-β1表达的影响[J].四川中医,2011,29(1)：8-10
[72]徐艳玲,曲妮妮,马丽佳,等.中药复方咳喘康对盐酸博莱霉素A5致肺纤维化大鼠肺系数及肺组织形态学影响的实验研究[J].中华中医药学刊,2009,27(1)：74-76
[73]刘恩顺.芪术合剂对肺纤维化大鼠TGF-β1表达及肺组织形态的影响[J].辽宁中医杂志,2008,35(2)：301-302
[74]张念志,许祥稳,李国琳,等.参七虫草胶囊对肺纤维化大鼠TGF-β1mRNA表达的影响[J].中国中医急症,2010,19(1)：89-91
[75]蔡望喜.中药益气化纤汤抗大鼠肺纤维化的实验研究[J].广州医药大学学报,2009,26(3)：263-264
[76]张晓梅.肺纤方治疗特发性肺间质纤维化临床研究[J].北京中医药,2009,28(4)：254-255
[77]魏文君.益气活血化痰方配合西药治疗肺纤维化30例[J].陕西中医,2009,30(8)：950-951
[78]龚婕宁,郭海,魏凯峰,等.养肺活血方对肺纤维化大鼠细胞外信号调节激酶1／2和核因子K-B信号通路的影响[J].中国中医药信息杂志,2009,16(11)：21-22
[79]王琴,刘世青,李长生,等.化瘀理肺方对肺纤维化大鼠MMP-2和TIMP-1表达 的影响[J].山东大学学报(医学版),2009,47(2)：14-17
[80]贾育新,王凤仪.敦煌古方“紫苏煎”对肺间质纤维化模型大鼠血清、肺组织中HYP、LDH含量的影响[J].甘肃中医,2008,21(4)：53-54
[81]耿义红.养肺活血方对肺纤维化大鼠肺组织α-SMA表达的影响[J].江苏中医药,2010,42(12)：69-70
[82]杨珂.扶正化瘀方抗肺纤维化的药物配伍作用特点[J].中医杂志,2009,50(8)：732-733
[83]张桂才,周贤梅,仇中叶.虎芪活血煎对肺纤维化大鼠肺组织HYP含量及TGF-β1mRNA表达的影响[J].吉林中医药,2007,27(11)：49-51.
[84]段斐.复方鳖甲软肝方防治肺纤维化细胞凋亡的实验研究[J].时珍国医国药,2008,19(5)：1054-1055
[85]陈瑶,汤军,徐志瑛.祛痰散瘀软坚中药对肺纤维化大鼠肺组织病理形态学及HYP含量的影响[J].浙江中医药大学学报,2009,33(1)：33-37
[86]李戎,周蜜娟,蔡永宁,等.艾灸“肺腧”“膏育”影响BLMAS诱导肺纤维化大鼠TGF-β表达实验研究[J].中国针灸,2005：790
[87]李国勤,李辉,刘丽,等.辨治特发性肺间质纤维化经验[J].中医杂志,2009,50(2)：122-123
[88]董瑞,秦洪义,刘苹.通络益肺协定方特发性肺纤维化单元疗法临床研究[J].中医中药,2008,12(4)：16-19
[89]李辉,代嫒嫒.益气破血方治疗气虚血瘀型特发性肺间质纤维化的临床观察[J].北京中医药,2010,2(11)：839-841
[90]陈山泉.自拟方治疗特发性肺纤维化的疗效观察[J].中国疗养医学,2011,20(4)：364
[91]张晓梅,孙雪松,姜良铎,等.芪红汤对特发性肺间质纤维化患者肺功能及血氧的影响[J].中医药临床杂志,2008,20(1)：35-36
[92]杨道文,单大玲.康金散治疗肺间质纤维化临床研究[J].中国中医急症,2009,18(1)：14-15
[93]谭漪,董滟,董慧君.补虚通络法治疗特发性肺纤维化的临床研究[J].时珍国医国药,2009,20(3)：713-714
[94]钟勇.芪参益气汤联合雾化吸入布地奈德治疗特发性肺纤维化56例临床疗效观察[J].中国现代药物应用,2010,4(10)：134-135
[95]易高众,张贻秋,贺兼斌等.黄芪联合糖皮质激素治疗特发性肺纤维化的临床疗效[J].临床肺科杂志,2010,15(2)：291-292
[96]白数培.川芎辅助治疗36例慢性特发性肺纤维化的临床观察[J].中国医疗前沿,2010,5(4)：26
[79]龙涛,李莹芪.参益气滴丸治疗特发性肺纤维化32例疗效分析[J].实用中西医结合临床,2011,11(10)：112
[98]杨美菊,朱红军.参附注射液对特发性肺纤维化的治疗作用[J].医药论坛杂志,2011,32(15)：169-170
[99]尹世琦,桑玉兰.丹红注射液治疗特发性肺纤维化患者的疗效观察[J].中西医结合心脑血管病杂志,2011,9(1)：116-117
[100]贾莉.苦参碱联合强的松治疗特发性肺纤维化临床观察[J].医学信息,2011,3：1067-1068
[101]董辉.抗纤舒肺颗粒治疗特发性肺间质纤维化临床观察[J].中国中医药信息杂志,2010,17(3)：61-62
[102]王增祥,于金源,刘铭珍.克肺宁胶囊治疗特发性肺间质纤维化70例临床观察[J].中国中医急症,2009,18(2)：188-189、216
[103]翁恒,曲中平.麦门冬汤加减治疗特发性肺间质纤维化32例临床观察[J].国医论坛,2008,23(1)：6-7
[104]翁惠,马登峰.清金汤治疗特发性肺纤维化临床研究[J].甘肃中医,2011,24(1)：40-41
[105]陈萍,李素云.中西医结合治疗特发性肺纤维化38例[J].光明中医,2009,24(3)：505-506
[106]郭玉琴,杨洁.血府逐瘀汤联合压缩雾化吸入普米克令舒治疗特发性肺间质纤维化临床研究[J].中国中医急症,2009,18(10)：1590-1591
[]07]徐慧卿.针药并用治疗特发性肺纤维化疗效观察[J].上海针灸杂志,2010,9(10)：641-642
[1]王飞,陈平,曹国平,等.补阳还五汤对肺纤维化大鼠肺泡巨噬细胞肿瘤坏死因子的影响[耳中药药理与临床,2005,21(3)：5-6.
[2]曹国平,王飞,陈平.补阳还五汤对博莱霉素诱导大鼠肺纤维化过程中羟脯氨酸的含量影响[J].甘肃中医,2007,20(2)：51-52
[3]李霞.宫晓燕治疗肺纤维化理论探讨[J].辽宁中医杂志,2012,39(1)：47-48
[4]宫晓燕,王泽玉,张永和.纤克颗粒治疗特发性肺纤维化实验研究[J].长春中医学院学报,2005,25(1)：70-71
[5]张欣,辛洪涛,于静,等.益气活血法对肺纤维化动物模型细胞因子表达的影响[J].山东大学学报(医学版)2005,43(12)：1129-1131
[6]孙增涛,廉富,魏葆琳.益气活血散结法治疗特发性肺纤维化临床与实验研究[J].辽宁中医杂志,2007,34(7)：865-867
[7]张欣,辛洪涛,李怀臣,等.芪丹颗粒对大鼠肺间质纤维化转化生长因子β1mRNA和肿瘤坏死因子mRNA表达的影响[J].中国临床康复,2005,9(31)：144-146
[8]张欣,辛洪涛,李怀臣,等.芪丹颗粒治疗肺间质纤维化的实验研究[J].山东医药,2005,45(20)：6-8
[9]刘恩顺,孙增涛,廉富,等.芪术合剂干预肺纤维化大鼠TGF-β1mRNA表达的实验研究[J].天津药学,2007,19(2)：1-3
[10]燕小宁,马华,赵瑞宝.中药芪红合剂对肺间质纤维化模型大鼠肺组织中TGF-β1表达的影响的影响[J].山西中医学院学报,2007,8(2)：11-13
[11]李瑞琴,宋建平,李伟,等.大黄蛰虫丸对肺纤维化模型形成阶段肺组织TNF-α 表达的影响[J].时珍国医国药,2010,21(1)：105-106
[12]张念志,许祥稳,李国琳,等.参七虫草胶囊对肺纤维化大鼠TGF-β1mRNA表达的影响[J].中国中医急症,2010,19(1)：89-91
[13]白文,王少杰王春玲,等.中药益气活血法对博莱霉素致肺纤维化小鼠IFN-C、IL-4的影响[J].北京中医药大学学报,2007,30(6)：401-405
[14]翟华强,杨毅,姜楠.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893
[15]郭书文,王国华,杨蟠储等.益气活血化痰方对肺纤维化大鼠支气管肺泡灌洗液中层粘连蛋白、III型前胶原含量的影响[J].中国中医药信息杂志,2006,13(11)：43-44
[16]刘玉庆,李谈,刘贵颖.益气活血方对肺纤维化黏附分子表达影响的实验研究[J].天津中医药,2009,26(1)：54-56
[17]关天宇,焦阳,杨效华,等.肺痹汤对肺间质纤维化大鼠血清细胞外基质影响的实验研究[J].中国中医基础医学杂志,2007,13(1)：50-51
[18]蒋宁.保肺方对肺间质纤维化大鼠模型细胞外基质代谢影响的实验研究[D].北京中医药大学博士学位论文,2004,6
[19]张永全.补阳还五汤治疗气虚血瘀型脑梗死的临床疗效及对血流速度的影响[J].中国中医急症,2010,19(8)：1288-1289
[20]黄清苑.补阳还五汤治疗缺血性中风对神经功能的影响[J].河北医学,2011,17(7)：973-974
[21]张利军.补阳还五汤治疗脑梗死临床疗效观察[J].中医药导报,2009,15(1)：23-24
[22]白会强.补阳还五汤对稳定性心绞痛患者CRP、IL-6和IL-1的影响及其相关性研究[J].中药药理与临床,2009,25(2)：110-113
[23]刘革命.补阳还五汤对冠状动脉粥样硬化性心脏病左室舒张功能的影响[J].河北中医,2009,31(11)：1658-1659
[24]秦永山.补阳还五汤治疗糖尿病周围神经病变128例[J].甘肃中医,2010,23(4)：47
[25]王琳,李伟,杨铭,等.黄芪皂苷注射液对急性心衰犬心功能和血流动力学的影响[J].中国老年医学杂志,2009,29(15)：1913-1915
[26]朱海燕.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子表达的影响[J].辽宁中医杂志,2008,35(1)：7-9
[27]林梦感,杨义芳,许海燕.黄芪多糖MAPS-5的化学结构及其体外淋巴细胞增殖活性[J].中草药,2009,40(12)：1865
[28]Lee K Y, Jeon Y J. Macrophage activation by polysaccharide iso-Lated from Astragalus membranaceus[J]. Int Immunopharmacol,2005,5(7/8):1225
[29]L H Zhao, Z X Ma, J Zhu, et al. Characterization of polysaccha-Ride from Astragalus radix as the macrophage stimulator[J]. CellImmunol,2011,271 (2):329
[30]廖苇萍,石元刚.黄芪多糖和大豆异黄酮对糖尿病大鼠糖代谢的影响[J].第三军医大学学报,2007,29(5)：416-418
[31]黄宏思.黄芪多糖协同抗癌药物对肿瘤细胞的杀伤作用[J].中国现代临床医学,2007,6(4)：35-37
[32]牛春红,刘斌焰,邢雁霞,等.黄芪多糖对四氯化碳肝损伤保护的影响[J].中国医学工程,2012,20(3)：38-39
[33]郑兰兵,魏青,刘小玲,等.黄芪多糖体外抗CVB病毒活性[J].中国医药指南,2011,9(13)：45-46
[34]赵莲芳,郑玉淑,朴惠顺,等.黄芪多糖及人参总皂苷对衰老小鼠的抗衰老作用[J].延边大学医学学报,2006,29(4)：249-251
[35]孙梅.黄芪多糖对LPS损伤小肠上皮细胞的保护作用[J].世界华人消化杂志,2008,16(1)：15-17
[36]Liu P J, Hsieh W T, Huang S H, et al. Hematopoietic effect of water-sol-ublepoly saccharides from Angelica sinensis on mice with acute bloodless[J]. Experiment al Hematology,2010,38:437
[37]柳永青.当归的化学成分与生物活性[J].沈阳航空航天医药,2009,20(11)：127
[38]杜小丽,王改琴,吴宏,等.当归多糖对小鼠造血细胞表面粘附分子表达的影响[J].重庆医科大学学报,2008,33(3)：274
[39]杨铁虹,贾敏,梅其炳.当归多糖对小鼠免疫功能的调节作用[J].中成药,2005,27(5)：563-565
[40]胡慧娟,杭秉茜,王明书.当归的抗炎作用[J].中国中药杂志,2009,16(11)：684-687
[41]聂蓉.当归多糖预防小鼠急性四氯化碳性肝损伤的研究[J].武汉工业学院学报,2008,27(4)：23
[42]黄海霞,莫晓燕,杜晓阳.赤芍总苷对培养乳鼠心肌细胞损伤后细胞凋亡的影响[J].时珍国药国医,2005,16(10)：963-965
[43]朱慧民,牟华明.赤芍对球囊损伤术后血管内膜单核细胞趋化蛋白-1基因表达的影响[J].中国中西医结合急救杂志,2008,15(3)：138-141
[44]何延龙,周端,董六一.赤芍总苷对大鼠局灶性脑缺血再灌注损伤的保护效果[J].中国临床康复,2006,10(39)：59-61
[45]许惠玉,陈志伟,牛建昭,等.赤芍总苷诱导K562细胞凋亡及对线粒体膜电位和Ca2+的影响[J].中国组织工程研究与临床康复,2008,12(16)：3123-3126
[46]Sheng H U, Chen S M, Li X K, et al. Antitumor effects of Chi-Shen extract from Salvia miltiorrhiza and Paeoniae Radix on human hepatocellular carcinoma cells[J]. Acta Pharma col Sin,2007,28(8):1215-1223
[47]Lv G, Zheng J, Zhou H, et al. The screening and isolation of an effective anti-endotoxin monomer from radix paeoniae rubra using affinity biosensor technology[J]. Int J Im munopharm ac ol,2005,5:1007-1017
[48]Lee B, Shin Y W, Bae E A,et al. Antiallergic effect of the Root of Paeonia lac tiflora and its constituents pae on iflor in And paeonol[J]. Arch Pharm Res,2008,31(4):445-450
[49]詹秀琴,戴启刚,樊文玲.地龙生物活性部位经膜分级分离后降压作用的比较研究[J]生物学通报,2010,45(9)：24-26
[50]杨明.高速逆流色谱分离地龙中抗血栓活性成分的研究[J].中国医药导刊,2010,12(7)：32-35
[51]刘英姿.地龙注射液免疫活性的体外研究[J].安徽农业科学,2009,37(35)：17514-17517
[52]杨明,陈学东,彭辑地龙蛋白组分对鼻咽癌裸鼠移植瘤微血管密度的影响[J].湖南中医药大学学报,2008,28(4)：46-47’
[53]王莉,刘毅,王芬,等.地龙对哮喘模型小鼠肺组织α-SMA及纤维蛋白的抑制作用[J].中医病理生理杂志,2009,25(10)：1964-1968
[54]陆亚琴,刘顺英,陈洪,等.地龙2号抑制大鼠肝纤维化的研究[J].胃肠病学及 肝病学杂志,2004,13(3)：225-227
[55]周苏宁.川芎嗪心血管药理的研究[J].中药药理与临床,2001,7(3)：311
[56]梁日欣,廖福龙,韩东.川芎嗪预处理对麻醉家兔心肌缺血再灌注损伤的保护作用[J].中药药理与临床,2000,16(2)：11
[57]黄美杏,陈学远,龙学明,等.川芎嗪对慢性肺心病急性加重期患者肺功能与血管活性物质的影响[J].实用医学杂志,2005,3(19)：602
[58]朱全刚,胡晋红,黄瑾,等.阿魏酸及其衍生物的药理作用[J].中药材,2001(7)：1992-2000
[59]文川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样硬化斑块炎症反应的影响[J].中国中西医结合杂志,2005,25(4)：345
[60]耿涛,谢梅林,彭少平.桃仁提取物抗大鼠心肌缺血作用的研究[J].苏州大学学报,2005,25(2)：238-240
[61]洪长福,娄金萍,周华仕,等.桃仁提取物对大鼠实验性矽肺纤维化的影响[J].劳动医学,2000,17(4)：218
[62]张晓平,陈建明,强世平,等.山桃仁水煎提取物对肝纤维化小鼠血清I、III型前胶原的降解作用[J].福建中医药,2002,33(4)：361
[63]邱蓉丽,李磷.桃仁正品来源品种脂肪油和氨基酸分析与比较[J].中国药师,2008,11(12)：1426-1428
[64]郑为超,陈铎葆,张雷,等.红花黄色素对缺血心肌的影响及机制研究[J].中国药理学通报,2005,21(8)：978-980
[65]臧宝霞,金鸣,司南,等.羟基红花黄色素A对血小板活化因子的拮抗作用[J].药学学报,2002,37(9)：696
[66]金鸣,高子淳,王继峰.羟基红花黄色素A抑制PAF诱发的家兔血小板活化的研究[J].北京中医药大学学报,2004,27(5)：32
[67]田京伟,傅风华,蒋王林,等.羟基红花黄色素A对脑缺血所致大鼠脑线粒体损伤的保护作用[J].药学学报,2004,39(10)：774
[68]梁辉,范金英,李爱华,等.羟基红花黄色素A对大鼠局灶性脑缺血再灌注NMDAR1蛋白表达的影响[J].中华老年心脑血管病杂志,2004,6(3)：194
[69]费娅丽,黄小民.红花注射液对大鼠内毒素性肝损伤保护机制的研究[J].中国中 医急症,2009,18(6)：948
[70]陈志强,王万强,叶秀云,等.红花注射液对脑缺血/再灌注损伤家兔血清白细胞介素IL-8的影响[J].中国急救医学,2005,25(2)：118
[71]金鸣,李金荣,吴伟.羟基红花黄色素A抗氧化作用的研究[J].中草药,2004,35(6)：665